WO2023224961A1 - Cancer therapy using a combination of a cdk7 inhibitor with an oral serd - Google Patents
Cancer therapy using a combination of a cdk7 inhibitor with an oral serd Download PDFInfo
- Publication number
- WO2023224961A1 WO2023224961A1 PCT/US2023/022340 US2023022340W WO2023224961A1 WO 2023224961 A1 WO2023224961 A1 WO 2023224961A1 US 2023022340 W US2023022340 W US 2023022340W WO 2023224961 A1 WO2023224961 A1 WO 2023224961A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- formula
- pharmaceutically acceptable
- amino
- Prior art date
Links
- 229940125888 CDK7 inhibitor Drugs 0.000 title abstract description 5
- OBJNFLYHUXWUPF-IZZDOVSWSA-N n-[3-[[5-chloro-4-(1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(e)-4-(dimethylamino)but-2-enoyl]amino]benzamide Chemical compound C1=CC(NC(=O)/C=C/CN(C)C)=CC=C1C(=O)NC1=CC=CC(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)=C1 OBJNFLYHUXWUPF-IZZDOVSWSA-N 0.000 title abstract description 5
- 238000011275 oncology therapy Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 267
- 238000000034 method Methods 0.000 claims abstract description 213
- 150000003839 salts Chemical class 0.000 claims abstract description 177
- 229940125944 selective estrogen receptor degrader Drugs 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 92
- 201000011510 cancer Diseases 0.000 claims abstract description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 66
- 206010006187 Breast cancer Diseases 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 52
- 208000026310 Breast neoplasm Diseases 0.000 claims description 51
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 35
- SIFNOOUKXBRGGB-AREMUKBSSA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical group C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 SIFNOOUKXBRGGB-AREMUKBSSA-N 0.000 claims description 34
- 229950005473 elacestrant Drugs 0.000 claims description 34
- GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 claims description 30
- KISZAGQTIXIVAR-VWLOTQADSA-N 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(CCC1)C=C(C=C2)C(=O)O)C1=CC=C(C=C1)O[C@@H]1CN(CC1)CCCF KISZAGQTIXIVAR-VWLOTQADSA-N 0.000 claims description 30
- 229940126088 GDC-9545 Drugs 0.000 claims description 30
- WDHOIABIERMLGY-CMJOXMDJSA-N N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine Chemical compound FCCCN1CC(C1)NC=1C=NC(=CC=1)[C@H]1N([C@@H](CC2=C3C(=CC=C12)NN=C3)C)CC(F)(F)F WDHOIABIERMLGY-CMJOXMDJSA-N 0.000 claims description 30
- 229940070192 amcenestrant Drugs 0.000 claims description 30
- 229940125164 camizestrant Drugs 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000001188 haloalkyl group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- -1 (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide fumarate Chemical compound 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- UVBQMXOKKDCBJN-MUUNZHRXSA-N (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol Chemical compound OC1=CC=C2C(=C1)N=CC1=C2[C@H](OC2=C1C=CC(=C2)C(F)(F)F)C1=CC=C(OCCN2CC(CF)C2)C=C1 UVBQMXOKKDCBJN-MUUNZHRXSA-N 0.000 claims description 16
- KOAITBOFZOEDOC-BJMVGYQFSA-N (E)-3-[4-[[2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxy-1-benzothiophen-3-yl]oxy]phenyl]prop-2-enoic acid Chemical compound FC1=CC(=C(C(=O)C2=C(C3=C(S2)C=C(C=C3)O)OC2=CC=C(C=C2)/C=C/C(=O)O)C(=C1)C)C KOAITBOFZOEDOC-BJMVGYQFSA-N 0.000 claims description 16
- 229940126389 imlunestrant Drugs 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 229940073462 rintodestrant Drugs 0.000 claims description 16
- SJXNPGGVGZXKKI-NYYWCZLTSA-N (E)-3-[4-[[2-[2-(1,1-difluoroethyl)-4-fluorophenyl]-6-hydroxy-1-benzothiophen-3-yl]oxy]phenyl]prop-2-enoic acid Chemical compound FC(C)(F)C1=C(C=CC(=C1)F)C1=C(C2=C(S1)C=C(C=C2)O)OC1=CC=C(C=C1)/C=C/C(=O)O SJXNPGGVGZXKKI-NYYWCZLTSA-N 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- CVAXNGIXLUILFO-QPJJXVBHSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O)=O CVAXNGIXLUILFO-QPJJXVBHSA-N 0.000 claims description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 13
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 13
- 206010017758 gastric cancer Diseases 0.000 claims description 13
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 201000011549 stomach cancer Diseases 0.000 claims description 13
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 12
- 229910003827 NRaRb Inorganic materials 0.000 claims description 12
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 201000010536 head and neck cancer Diseases 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 208000009956 adenocarcinoma Diseases 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- ZNHSMYOYLFQLTL-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O)=O ZNHSMYOYLFQLTL-ZZXKWVIFSA-N 0.000 claims description 6
- FTHWKDSNIHXRKG-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-pyrrolidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCC1)=O)=O FTHWKDSNIHXRKG-VMPITWQZSA-N 0.000 claims description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- CVAXNGIXLUILFO-KPGJNUASSA-N (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound CC(C)[C@H](C(NC1=NNC(C2CC2)=C1)=O)C1=CC=CC(C(C=C2)=CN=C2NC(/C=C/CN2CCOCC2)=O)=C1 CVAXNGIXLUILFO-KPGJNUASSA-N 0.000 claims description 4
- DGWRKYUYWBECQL-XBXARRHUSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-(3-fluoropiperidin-1-yl)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CC(CCC1)F)=O)=O DGWRKYUYWBECQL-XBXARRHUSA-N 0.000 claims description 3
- FELGDXDUEDTBOE-NEKWBUCNSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[(3S)-3-fluoropyrrolidin-1-yl]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1C[C@H](CC1)F)=O)=O FELGDXDUEDTBOE-NEKWBUCNSA-N 0.000 claims description 3
- CVAXNGIXLUILFO-ZGQXNYPMSA-N CC(C)[C@@H](C(NC1=NNC(C2CC2)=C1)=O)C1=CC=CC(C(C=C2)=CN=C2NC(/C=C/CN2CCOCC2)=O)=C1 Chemical compound CC(C)[C@@H](C(NC1=NNC(C2CC2)=C1)=O)C1=CC=CC(C(C=C2)=CN=C2NC(/C=C/CN2CCOCC2)=O)=C1 CVAXNGIXLUILFO-ZGQXNYPMSA-N 0.000 claims description 3
- PXIACUPZCJZCBF-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-(prop-2-enoylamino)pyridin-3-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(C=C)=O)=O PXIACUPZCJZCBF-UHFFFAOYSA-N 0.000 claims description 3
- SRWPGRUPJNPGRS-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridin-3-yl]phenyl]-3-methylbutanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(C)C)=O)=O SRWPGRUPJNPGRS-RMKNXTFCSA-N 0.000 claims description 3
- QYHNACRNROAGBW-RMKNXTFCSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCCC1)=O)=O QYHNACRNROAGBW-RMKNXTFCSA-N 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 50
- 239000011159 matrix material Substances 0.000 description 32
- 239000003814 drug Substances 0.000 description 31
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 238000009472 formulation Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 230000003833 cell viability Effects 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 11
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 8
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000282320 Panthera leo Species 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102100038595 Estrogen receptor Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000008732 thymoma Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KSWGPYWKISIVQN-UHFFFAOYSA-N 2-(3-bromophenyl)-3-methylbutanoic acid Chemical compound CC(C)C(C(O)=O)C1=CC=CC(Br)=C1 KSWGPYWKISIVQN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- WBRFZYYYZORXSK-UHFFFAOYSA-N CC(C)C(C(NC1=NN(C(OC(C)(C)C)=O)C(C2CC2)=C1)=O)C1=CC(Br)=CC=C1 Chemical compound CC(C)C(C(NC1=NN(C(OC(C)(C)C)=O)C(C2CC2)=C1)=O)C1=CC(Br)=CC=C1 WBRFZYYYZORXSK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 206010028729 Nasal cavity cancer Diseases 0.000 description 2
- 206010028767 Nasal sinus cancer Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 229910020008 S(O) Inorganic materials 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 201000009365 Thymic carcinoma Diseases 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 229940126003 ZN-c5 Drugs 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001983 electron spin resonance imaging Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 201000007052 paranasal sinus cancer Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- JLSUNTPGMCLMPI-OWOJBTEDSA-N (E)-N-(5-bromopyridin-2-yl)-4-morpholin-4-ylbut-2-enamide Chemical compound BrC=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O JLSUNTPGMCLMPI-OWOJBTEDSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- IJQAUHSTPIEQRZ-UHFFFAOYSA-N CC(C)C(C(NC1=NN(C(OC(C)(C)C)=O)C(C2CC2)=C1)=O)C1=CC(B2OC(C)(C)C(C)(C)O2)=CC=C1 Chemical compound CC(C)C(C(NC1=NN(C(OC(C)(C)C)=O)C(C2CC2)=C1)=O)C1=CC(B2OC(C)(C)C(C)(C)O2)=CC=C1 IJQAUHSTPIEQRZ-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000002495 Cyclin H Human genes 0.000 description 1
- 108010068237 Cyclin H Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229940125641 estrogen receptor degrader Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 208000018819 hormone-resistant breast carcinoma Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- YQDHRHYFLKUTQX-UHFFFAOYSA-N tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1N=C(N)C=C1C1CC1 YQDHRHYFLKUTQX-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Definitions
- This invention pertains to methods for treating cancer in a subject, comprising administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with an oral selective estrogen receptor degrader (SERD).
- SESD selective estrogen receptor degrader
- Cyclin-dependent kinase is necessary for transcription and acts by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (PolII) to enable transcription initiation.
- CDK7 also modulates regulated gene expression by phosphorylating transcription factors, including p53, retinoid receptors, androgen receptor, and estrogen receptor.
- Ligand-dependent phosphorylation of serine 118 (Seri 18), important for ERa function and turnover, is mediated by CDK7 (Oncogene; 2002; 21:4921).
- pharmacological modulation of CDK7 kinase activity is considered to be an important approach to treat cancers that are critically dependent on transcription to maintain their oncogenic state.
- CDK7 which complexes with cyclin H and MAT1, phosphorylates the cell cycle CDKs in the activation of T-loop, to promote their activities (Fisher et al., Cell., Aug 26;78(4):713-24, 1994). Recent genetic and biochemical studies have confirmed the importance of CDK7 for cell cycle progression (Larochelle et al., Mol Cell., Mar 23;25(6):839-50. 2007; Ganuza et al., EMBO J., May 30; 31(11): 2498-510, 2012).
- Oral SERDs having SERD activity with good oral bioavailability, are being developed to allow for convenient oral administration for treatment of cancers, including ER+ breast cancer. Oral SERDs are also being investigated in other cancers such as ovarian cancer and endometrial cancer.
- the present invention provides methods and compositions for treating cancer using a compound of formula (I) or a pharmaceutically acceptable salt thereof, including combination therapy with an oral selective estrogen receptor degrader (SERD).
- SESD selective estrogen receptor degrader
- a method of treating cancer in a subject comprising administering to the subject a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
- Ri is hydrogen or alkyl
- R2 is hydrogen, alkyl or cycloalkyl
- R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl; or wherein R5' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)I-3- NR a R b ; R 5 " is H or alkyl;
- R a and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl ; alternatively, R a and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
- R6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- L1 is *-CRcRd -C(O)-, *-NReC(O)- or absent; wherein * is the point of attachment with ring A;
- R c and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, R c and Rd together with the carbon atom to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L2 is -C(O)NH-, — C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1 ; and q is 0 to 3.
- a use of a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with an oral SERD for the treatment of cancer for the treatment of cancer.
- the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
- the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
- the cancer is breast cancer.
- the cancer is metastatic breast cancer.
- the cancer is metastatic hormone resistant breast cancer.
- the cancer is ER-positive (estrogen receptor positive), HRpositive (hormone receptor positive, i. c. , ER-positive and progesterone receptor (PR)- positive) or HER2 -negative (human epidermal growth factor receptor 2 negative), advanced or metastatic breast cancer.
- HRpositive hormone receptor positive, i. c. , ER-positive and progesterone receptor (PR)- positive
- HER2 -negative human epidermal growth factor receptor 2 negative
- the cancer is non-small cell lung cancer.
- Fig. 1 is a cell viability matrix for CPD-44A + amcenestrant in a MCF7 cell line.
- Fig. 2 is a cell viability matrix for CPD-44A + giredestrant in a MCF7 cell line.
- Fig. 3 is a cell viability matrix for CPD-44A + camizestrant in a MCF7 cell line.
- Fig. 4 is a cell viability matrix for CPD-44A + elacestrant in a MCF7 cell line.
- Fig. 5 is a cell viability matrix for CPD-44A + amcenestrant in a BT474 cell line.
- Fig. 6 is a cell viability matrix for CPD-44A + giredestrant in a BT474 cell line.
- Fig. 7 is a cell viability matrix for CPD-44A + camizestrant in a BT474 cell line.
- Fig. 8 is a cell viability matrix for CPD-44A + elacestrant in a BT474 cell line.
- Fig. 9 is a cell viability matrix for CPD-44A + amcenestrant in a T47D cell line.
- Fig. 10 is a cell viability matrix for CPD-44A + giredestrant in a T47D cell line.
- Fig. 11 is a cell viability matrix for CPD-44A + camizestrant in a T47D cell line.
- Fig. 12 is a cell viability matrix for CPD-44A + elacestrant in a T47D cell line.
- Fig. 13 is a Loewe synergy score matrix for CPD-44A + amcenestrant in a MCF7 cell line.
- Fig. 14 is a Loewe synergy score matrix for CPD-44A + elacestrant in a MCF7 cell line.
- Fig. 15 is a Loewe synergy score matrix for CPD-44A + giredestrant in a MCF7 cell line.
- Fig. 16 is a Loewe synergy score matrix for CPD-44A + camizestrant in a MCF7 cell line.
- Fig. 17 is a plot of median tumor volume in a MCF7 mouse xenograft model following dosing of CPD-44A, elacestrant, or a combination thereof.
- alkyl alone or in combination with other term(s) means saturated aliphatic hydrocarbon chains, including Ci-Cio straight or C3-C10 branched alkyl groups.
- alkyl include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl and the like.
- halo or “halogen” alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
- haloalkyl means alkyl substituted with one or more halogen atoms independently, wherein the alkyl groups are as defined above.
- halo is used herein interchangeably with the term “halogen” means F, Cl, Br or I.
- haloalkyl include but are not limited to fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
- hydroxy or “hydroxyl” alone or in combination with other term(s) means -OH.
- alkoxy refers to the group alkyl-O- or -O-alkyl, where alkyl groups are as defined above.
- alkoxy- groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy and the like.
- An alkoxy group can be unsubstituted or substituted independently with one or more suitable groups.
- alkoxyalkyl refers to the group alkyl-O-alkyl-, wherein alkyl and alkoxy groups are as defined above.
- alkoxyalkyl- groups include but are not limited to methoxymethyl, ethoxymethyl, methoxyethyl, isopropoxymethyl and the like.
- cyano refers to -CN; and the term “cyanoalkyl” refers to alkyl substituted with -CN; wherein the alkyl groups are as defined above.
- amino refers to -NH2
- nitro refers to -NO2
- acyl refers to the group -C(O)-alkyl, wherein alkyl groups are as defined above.
- exemplary acyl- groups include but are not limited to acetyl, propanoyl and acrylyl.
- An acyl group can be unsubstituted or substituted independently with one or more suitable groups.
- cycloalkyl alone or in combination with other term(s) means C3-C10 saturated cyclic hydrocarbon ring.
- a cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- a cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused and spirocyclyls and the like.
- aryl is optionally substituted monocyclic, bicyclic or polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms.
- C6-C14 aryl group include, but are not limited to phenyl, naphthyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl.
- An aryl group can be unsubstituted or substituted independently with one or more suitable groups.
- heterocycloalkyl refers to a non-aromatic, saturated or partially saturated monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or hetero group selected from O, N, S, S(O), S(O)2, NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur.
- a monocyclic heterocycloalkyl may typically contain 4 to 7 ring atoms.
- heterocycloalkyl examples include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl and N-oxides thereof. Attachment of a heterocycloalkyl substituent can occur via either a carbon atom or a heteroatom.
- a heterocycloalkyl group can be optionally independently substituted with one or more suitable groups selected from one or more aforesaid groups.
- heteroaryl alone or in combination with other term(s) means a completely unsaturated ring system containing a total of 5 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms/groups being independently selected from the group consisting of carbon, oxygen, nitrogen or sulfur.
- a heteroaryl may be a single-ring (monocyclic) or polycyclic ring system. Examples of “heteroaryl” include but are not limited to pyridyl, indolyl, benzimidazolyl, benzothiazolyl and the like.
- heterocyclyl alone or in combination with other term(s) includes both “heterocycloalkyl” and “heteroaryl” groups which are as defined above.
- heteroatom designates a sulfur, nitrogen or oxygen atom.
- the term “optionally substituted” or “substituted” or “optionally substituted with suitable groups” refers to replacement of one or more hydrogen radicals in a given structure with a radical of a specified substituent including, but not limited to halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino
- treatment means any treatment of a disease in a mammal, including (a) Inhibiting the disease, i.e., slowing or arresting the development of clinical symptoms; and/or (b) Relieving the disease, i.e., causing the regression of clinical symptoms and/or (c) Alleviating or abrogating a disease and/or its attendant symptoms.
- “Pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- pharmaceutically acceptable salt refers to a product obtained by reaction of the compound of the present invention with a suitable acid or a base.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Al, Zn and Mn salts.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic/organic acids such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, 4-methylbenzenesulfonate or p-toluenesulfonate salts, and the like.
- inorganic/organic acids such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, isonic
- Certain compounds of the invention can form pharmaceutically acceptable salts with various organic bases such as lysine, arginine, guanidine, diethanolamine or metformin.
- Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc, salts.
- stereoisomers refers to any enantiomers, diastereomers, or geometrical isomers of the compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG), wherever they are chiral or when they bear one or more double bonds.
- compounds of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG) are chiral, they can exist in racemic or in optically active form.
- the invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric and epimeric forms, as well as tZ-isomers and l- isomers and mixtures thereof.
- Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art.
- Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
- the compounds of the present invention may exist as geometric isomers.
- the present invention includes all cis/trans, syn/anti,
- Z)/(S) isomers as well as the appropriate mixtures thereof.
- the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
- Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2 H (“D”), 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 C1, 123 I and 125 I.
- Isotopically labeled compounds of the present inventions can generally be prepared by following procedures well known in the art, such as by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- the term “subject” refers to an animal, preferably a mammal, and most preferably a human.
- the term, “therapeutically effective amount” refers to an amount of a compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer thereof; or a composition comprising the compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer thereof, effective in producing the desired therapeutic response in a particular patient suffering from cancer.
- the term “therapeutically effective amount” includes the amount of the compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer thereof, when administered, that induces a positive modification in the disease or disorder to be treated or is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease or disorder being treated in a subject.
- the amount of the compound used for the treatment of a subject is low enough to avoid undue or severe side effects, within the scope of sound medical judgment can also be considered.
- the therapeutically effective amount of the compound or composition will be varied with the condition being treated, the severity of the condition being treated, the duration of the treatment, the nature of concurrent therapy, the age and physical condition of the end user, the specific compound or composition employed the particular pharmaceutically acceptable carrier utilized.
- oral SERD refers to a therapeutic compound that possesses biological activity as a selective estrogen receptor degrader and has adequate oral bioavailability to be suitable for oral administration.
- an oral SERD has oral bioavailability that is greater than SERDs that are not suitable for oral administration due to their poor oral bioavailability (e.g., fulvestrant).
- compounds of the invention may be used in combination with another therapeutic agent.
- administering a first agent e.g., a compound of formula (I)
- a second agent e.g., an oral SERD
- administering a first agent e.g., a compound of formula (I)
- a second agent e.g., an oral SERD
- administering a first agent e.g., a compound of formula (I)
- a second agent e.g., an oral SERD
- the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially.
- the different therapeutic compounds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another.
- the second agent is administered within about 5 minutes to within about 168 hours prior to or after administration of the first agent.
- a subject who receives such treatment can benefit from a combined effect of the administered therapeutic compounds.
- the present invention provides methods wherein an oral SERD is administered within about 5 minutes to within about 168 hours prior to or after administration of a compound of formula (I).
- the present invention provides methods wherein an oral SERD is administered within 0.5 hours to 72 hours prior to or after administration of a compound of formula (I).
- the present invention provides methods wherein an oral SERD is administered within 0.5 hours to 24 hours prior to or after administration of a compound of formula (I). In some embodiments, the present invention provides methods wherein an oral SERD is administered within 2 hours prior to or after administration of a compound of formula (I).
- the present invention provides methods comprising administering a compound of formula (I) prior to administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (1) 2 hours prior to administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) within 0.5 hours to 72 hours after administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) about 2 hours after administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) at least 1 hour after an oral SERD.
- combination therapy of compounds of the invention with one or more additional therapeutic agent(s) provide improved efficacy relative to each individual administration of the compound of the invention or the one or more additional therapeutic agent(s).
- the combination therapy provides an additive effect, wherein an additive effect refers to the sum of each of the effects of individual administration of the compound of the invention and the one or more additional therapeutic agent(s).
- a method of treating cancer in a subject comprising administering to the subject a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
- Ri is hydrogen or alkyl
- R2 is hydrogen, alkyl or cycloalkyl
- R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R5 is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)i-3- NR a Rb; R 5 " is H or alkyl;
- R a and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, R a and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
- R 5 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- Li is *-CRcRd-C(O)-, *- -NReC(O)- or absent; wherein * is the point of attachment with ring A;
- R c and Ri independently are hydrogen, alkyl or haloalkyl; alternatively, R c and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L2 is -C(O)NH- — C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
- the present methods include administering a compound of formula (I) represented by formula (IA): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
- Ri is hydrogen or alkyl
- R2 is hydrogen, alkyl or cycloalkyl
- R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy or alkoxy; ; wnerem KS IS nyarogen, naio, aiKyi, aiKoxy, aiKoxyaucyi or - (CH 2 )i-3-NR a Rb; R 5 " is H or alkyl;
- R a and Rb are each independently hydrogen or alkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0- 2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
- Li is *-CRcRd-C(O)-, *-NR e C(O)- or absent; wherein * is the point of attachment with ring A;
- R c and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, R c and Rd together with the carbon atom to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L2 is -C(O)NH-, -C(O)O- or absent; m is 0, 1 or 2; and p is 0 or 1.
- the present methods include administering a compound of formula (1) represented by formula (IB): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
- the present methods include administering a compound of formula (I) represented by formula (IC): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
- the present methods include administering a compound of formula (I) represented by formula (ID): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
- the present methods include administering a compound of formula (I) represented by formula (IE):
- the present methods include administering a compound of formula (I) represented by formula (IF): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Li is and wherein * is the point of attachment with phenyl ring.
- the present methods include administering a compound of formula (I) represented by formula (IG): or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
- a method of treating breast cancer in a subject comprising administering to the subject a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
- Ri is hydrogen or alkyl
- R2 is hydrogen, alkyl or cycloalkyl
- R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl; or wherein R5' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)I-3- NR a Rb; R 5 " is H or alkyl;
- R a and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, R a and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
- R 5 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- Li is *-CRcR ⁇ i-C(O)-, *-NR «C(O)- or absent; wherein * is the point of attachment with ring A;
- R c and Ri independently are hydrogen, alkyl or haloalkyl; alternatively, R c and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L2 is -C(O)NH-, -C(0)0- or absent
- m is 0, 1 or 2
- p is 0 or 1
- q is 0 to 3.
- the present methods include administering a compound of formula (I) wherein ring A is aryl or heteroaryl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is aryl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is 1,3-phenylene.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is monocyclic or bicyclic, cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
- the present methods include administering compounds of formula (I), wherein ring B is aryl.
- ring B is aryl.
- the aryl is phenyl.
- the present methods include administering compounds of formula (I), wherein ring B is heterocyclyl.
- the heterocyclyl is piperidinyl, pyridinyl, piperazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is cycloalkyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is:
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 ' is -(CH2)i-3-NRaRb.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R a and Rb together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N.
- the present methods include administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein Li is *-CR c Rd-C(O)-; wherein * is the point of attachment with ring A.
- methods which include administering a compound of formula (I), wherein Rc and Rd are independently hydrogen or alkyl, wherein the alkyl is methyl, ethyl or isopropyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein L2 is absent.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein when Li is present, L2 is absent.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is alkyl or cycloalkyl.
- R2 is alkyl or cycloalkyl.
- the alkyl is ethyl and the cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen and alkyl; wherein the alkyl is methyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R4 is halo.
- R4 is halo.
- the halo is fluoro.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is: wherein R5' is hydrogen or -CH2-NR a Rb.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: when R 5 is attached to hetero atom of ring B; R 5 ' is hydrogen or -CH2-NR a Rb.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the R a and Rb are each independently hydrogen or alkyl.
- the alkyl is methyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, hydroxy, haloalkyl or alkoxy.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is meta-substituted with respect to Li and L2.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is monocyclic or bicyclic, cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is heterocyclyl.
- the heterocyclyl is piperidinyl, pyridinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
- the present methods include administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein m is 1.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 1.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is cycloalkyl; in another embodiment, the cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and Ri together with the atoms to which they are attached form a 5 or 6 membered ring.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and R3 together with the atoms to which they are attached form a 5 or 6 membered ring.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and R3 together with the atoms to which they are attached form a 6 membered aromatic ring.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein R 5 ' is hydrogen, halo, alkyl, alkoxy or alkoxyalkyl; and R 5 " is H or alkyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein R 5 ' is -CH2-NR a Rb; R 5 " is H or alkyl; R a and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein R 5 ' is -CH2-NR a Rb; R 5 " is H or alkyl; R a and Rb together with the nitrogen atom to which they are attached form an optionally substituted 4-7 membered heterocyclyl ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein p is 1 , Ra and Rb are as defined in formula (I).
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 is: wherein '- is a point of attachment.
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5 ' is -(CH2)i-3-NRaRb; wherein R a and Rb are as defined in formula (I).
- the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein when Li is -CR c Ra-C(O)- or -NR e C(O)-, L2 is absent.
- the present methods include administering a compound of formula (I) selected from Table 1 below:
- Table 1 or a pharmaceutically acceptable salt or a stereoisomer thereof.
- the compound of formula (I) is selected from:
- the compound of formula (I) is selected from:
- the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (.S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)aniino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (7?)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- the present methods include administering a compound of formula (I) in combination with an oral SERD selected from elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
- an oral SERD selected from elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
- the oral SERD is elacestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is rintodestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is giredestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is amcenestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is camizestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is imlunestrant or a pharmaceutically acceptable salt thereof.
- the oral SERD is LSZ-102 or a pharmaceutically acceptable salt thereof.
- the oral SERD is ZN-c5, D-0502, or SHR9549, or a pharmaceutically acceptable salt thereof.
- compound of formula (I) is compound 44A (“CPD-44A”) of Table 1, which is (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
- CPD-44A compound 44A
- Table 1 is (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
- the structure of compound 44A is shown below:
- compound of formula (I) is a CDK7 inhibitor.
- the present methods include administering a compound of formula (I) in combination with an oral SERD, wherein the combination therapy provides a synergistic effect.
- the compound of formula (I) and the oral SERD are administered simultaneously or sequentially.
- the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
- the cancer is breast cancer.
- the cancer is metastatic breast cancer.
- the cancer is ER-positive, HR-positive or HER2 -negative, advanced or metastatic breast cancer.
- the cancer is ER-positive breast cancer.
- the cancer may be characterized by one or more mutations in estrogen receptor 1 (ESRI) that confer estrogen-independent ER activation and resistance to certain therapies such as aromatase inhibitors.
- ESRI estrogen receptor 1
- Examples of such mutations include ligand binding domain mutations such as D538G, Y537S, Y537N, Y537C, L536H, L536P, L536R, S463P, and E380Q. See, Brett, et al. Breast Cancer Res 23, 85 (2021), which is incorporated herein by reference in its entirety.
- the ER-positive breast cancer is characterized by a wild-type ER (e.g., wild-type ESRI).
- the cancer is HR-positive breast cancer, i.e., the cancer is ER-positive and progesterone receptor (PR)-positive.
- PR progesterone receptor
- the cancer is non-small cell lung cancer.
- the cancer is ER-positive ovarian cancer.
- the cancer is ER-positive epithelial cancer.
- the cancer is epithelial ovarian cancer.
- the cancer is triple negative breast cancer.
- cancer is metastatic castration-resistant prostate cancer.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an oral SERD, a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention provides a method of treating breast cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of ( ⁇ S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide or a pharmaceutically acceptable salt thereof in combination with an oral SERD.
- the breast cancer is ER-positive, HR-positive or HER2 -negative, advanced or metastatic breast cancer.
- the present methods comprise administering a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.
- the therapeutically effective amount of a compound of formula (I) is a total daily dosage of from about 5 mg to about 500 mg.
- the therapeutically effective amount of a compound of formula (I) is a total daily dosage of from about 10 mg to about 250 mg. In some embodiments, the total daily dosage is from about 20 mg to about 160 mg.
- the total daily dosage is from about 20 mg to about 80 mg. In some embodiments, the total daily dosage is from about 20 mg to about 40 mg. In some embodiments, the total daily dosage is from about 40 mg to about 160 mg. In some embodiments, the total daily dosage is from about 40 mg to about 80 mg. In some embodiments, the total daily dosage is from about 80 mg to about 160 mg. In some embodiments, the total daily dosage is about 20 mg, about 40 mg, about 80 mg, or about 160 mg.
- the present methods comprise administering a therapeutically effective amount of compound 44A or a pharmaceutically acceptable salt or a stereoisomer thereof.
- the therapeutically effective amount of Compound 44A or a pharmaceutically acceptable salt thereof is a total daily dosage of from about 5 mg to about 500 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 10 mg to about 250 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 80 mg.
- the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 40 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 40 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 40 mg to about 80 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 80 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is about 20 mg, about 40 mg, about 80 mg, or about 160 mg.
- the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof is administered orally.
- the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof e.g., Compound 44A or a pharmaceutically acceptable salt thereof
- the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof e.g., Compound 44A or a pharmaceutically acceptable salt thereof
- the total dose of the compound of formula (I) e.g., Compound 44-A
- a pharmaceutically acceptable salt e.g., Compound 44-A fumarate
- a stereoisomer thereof is from about 60 mg to about 100 mg, administered in two separate administrations per day, e.g., from about 30 mg to about 50 mg twice daily (BID).
- the total dose of the compound or pharmaceutically acceptable salt e.g., Compound 44-A fumarate
- the total dose of the compound or pharmaceutically acceptable salt is 80 mg, administered in two separate administrations per day, e.g., 40 mg twice day (BID).
- the present methods comprise administering a therapeutically effective amount of an oral SERD.
- the present methods comprise administering a therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof.
- Elacestrant, compositions thereof, and methods of use thereof are described in U.S. Patent Nos. 7,612,114; 8,399,520; 10,071,066; 10,385,008; 10,420,734; and 10,745,343, the entire contents of each of which are incorporated herein by reference.
- the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 500 mg, e.g., about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg.
- the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 500 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 250 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 100 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, elacestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 1,000 mg, e.g., about 50 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1,000 mg.
- the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 200 mg to about 1,000 mg.
- the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 500 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 300 mg. In some embodiments, rintodestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 50 mg, e.g., about 1 mg, about 2 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg.
- the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 5 mg to about 50 mg.
- the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 25 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 10 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 20 mg. In some embodiments, giredestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 400 mg, e.g., about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg.
- the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 400 mg.
- the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 200 mg.
- the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 100 mg. In some embodiments, the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 20 mg to about 200 mg. In some embodiments, amcenestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 100 mg, e.g., about 2 mg, about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 75 mg, or about 100 mg.
- the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 100 mg.
- the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 50 mg.
- the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 25 mg. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 5 mg to about 50 mg. In some embodiments, camizestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 500 mg, e.g., about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg.
- the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 500 mg.
- the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 250 mg.
- the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 100 mg. In some embodiments, the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, imlunestrant or a pharmaceutically acceptable salt thereof is administered once daily.
- the present methods comprise administering a therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 900 mg, e.g., about 50 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 900 mg.
- the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 200 mg to about 900 mg.
- the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 500 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 300 mg. In some embodiments, LSZ-102 or a pharmaceutically acceptable salt thereof is administered once daily.
- COMPOUND 44A is in the form of a salt or cocrystal of COMPOUND 44A. In some embodiments, COMPOUND 44A is in the form of a salt. In some embodiments, the salt is crystalline. In some embodiments, COMPOUND 44A is in the form of a cocrystal. In some embodiments, COMPOUND 44A is in the form of a fumaric acid salt or cocrystal. In some embodiments, the fumaric acid salt is crystalline. In some embodiments, COMPOUND 44A fumarate is a cocrystal of crystalline Form 1, as described in WO 2022/130304 AL In some embodiments, the molar ratio of COMPOUND A to fumaric acid is 1 : 1. In some embodiments, the COMPOUND 44A fumarate is anhydrous. In some embodiments, the salt or cocrystal comprises greater than or equal to 98 wt% of COMPOUND A fumarate by weight of the salt or cocrystal.
- the present methods include a pharmaceutical composition comprising one or more of the compounds as disclosed herein, optionally admixed with a pharmaceutically acceptable carrier or diluent.
- composition(s) of the present invention can be administered orally, for example in the form of tablets, coated tablets, pills, capsules, granules or elixirs. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injectable sterile solutions or suspensions, or topically, for example in the form of ointments or creams or transdermals, in the form of patches, or in other ways, for example in the form of aerosols or nasal sprays.
- An oral SERD is administered orally and formulated for oral administration.
- the pharmaceutical composition(s) usually contain(s) about 1% to 99%, for example, about 5% to 75%, or from about 10% to about 30% by weight of the compound of formula (I) or pharmaceutically acceptable salts thereof.
- the amount of the compound of formula (I) or pharmaceutically acceptable salts thereof in the pharmaceutical composition(s) can range from about 1 mg to about 500 mg or from about 2.5 mg to about 250 mg or from about 5 mg to about 50 mg.
- the present invention also provides methods for formulating the disclosed compounds as for pharmaceutical administration.
- compositions and methods of the present invention may be utilized to treat an individual in need thereof.
- the individual is a mammal such as a human, or a non-human mammal.
- the composition or the compound is preferably administered as a pharmaceutical composition comprising, for example, a compound of the invention and a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters.
- the aqueous solution is pyrogen-free, or substantially pyrogen- free.
- the excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs.
- the pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like.
- the composition can also be present in a transdermal delivery system, e.g., a skin patch.
- the composition can also be present in a solution suitable for topical administration, such as an eye drop.
- a pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the invention.
- physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
- carbohydrates such as glucose, sucrose or dextrans
- antioxidants such as ascorbic acid or glutathione
- chelating agents such ascorbic acid or glutathione
- low molecular weight proteins or other stabilizers or excipients include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients.
- the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent depends, for example, on the route of administration of the composition.
- the pharmaceutical composition also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the invention.
- Liposomes for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
- phrases “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydrox
- a pharmaceutical composition can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); anally, rectally or vaginally (for example, as a pessary, cream or foam); parenterally (including intramuscularly, intravenously, subcutaneously or intrathecally as, for example, a sterile solution or suspension); nasally; intraperitoneally; subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin, or as an eye drop).
- the compound may also be formulated for inhalation.
- a pharmaceutical composition for example, drenches
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- the pharmaceutical composition comprises the active ingredient in an amount of at least about 50% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 60% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 70% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 80% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 90% by weight of the composition.
- the oral pharmaceutical composition comprising the active ingredient of the present invention is a unit dose composition.
- the active ingredient is a compound of formula (I).
- the active ingredient is selected from: (E)-N-(5-(3-(l-((5- cyclopropyl- 1 H-pyrazol-3-yl)amino)-3-methyl- 1 -oxobutan-2-yl)phenyl)pyri din-2 -yl)-4- morpholinobut-2-enamide; (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 - oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-l-yl)but-2-enamide; and (E)-N-(5-(3-(l- ((5-cyclopropyl-lH-pyrazol-3-yl)amino)-l-oxopropan-2-yl)phenyl)pyridin-2-yl
- the active ingredient is (E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- the active ingredient is ( 1 S)-(E)-N-(5-(3-(l-((5-cyclopropyl- lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- the active ingredient is (7?)-(E)-N-(5-(3-(l-((5-cyclopropyl- lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
- Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the invention, with the carrier and, optionally, one or more accessory ingredients.
- an active compound such as a compound of the invention
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in- water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- Compositions or compounds may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7)
- pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose,
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- the active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art,
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as a suppository, which may be prepared by mixing one or more active compounds with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the pharmaceutical compositions for administration to the mouth may be presented as a mouthwash, or an oral spray, or an oral ointment.
- compositions can be formulated for delivery via a catheter, stent, wire, or other intraluminal device. Delivery via such devices may be especially useful for delivery to the bladder, urethra, ureter, rectum, or intestine.
- Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the active compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Ophthalmic formulations eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
- Exemplary ophthalmic formulations are described in U.S. Publication Nos. 2005/0080056, 2005/0059744 and U.S. Pat. No. 6,583,124, the contents of which are incorporated herein by reference.
- liquid ophthalmic formulations have properties similar to that of lacrimal fluids, aqueous humor or vitreous humor or are compatible with such fluids.
- a preferred route of administration is local administration (e.g., topical administration, such as eye drops, or administration via an implant).
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
- compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- biodegradable polymers such as polylactide-polyglycolide.
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- active compounds can be given per se or as a pharmaceutical composition containing, for example, about 0.1 to about 99.5% (more preferably, about 0.5 to about 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- Methods of introduction may also be provided by rechargeable or biodegradable devices.
- Various slow-release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals.
- a variety of biocompatible polymers including hydrogels, including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- terapéuticaally effective amount is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).
- a suitable daily dose of a pharmaceutically active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- the effective daily dose of the pharmaceutically active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- the pharmaceutically active compound may be administered two or three times daily. In preferred embodiments, the pharmaceutically active compound will be administered once daily.
- the patient receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- the compounds of the present invention may be administered in combination with one or more other drugs (1) to complement and/or enhance therapeutic efficacy of the therapeutic drug effect of the compound of the present invention, (2) to modulate pharmacodynamics, improve absorption improvement, or reduce dosage reduction of the therapeutic compound of the present invention, and/or (3) to reduce or ameliorate the side effects of the therapeutic compound of the present invention.
- the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially.
- the different therapeutic compounds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another.
- an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds.
- the respective compounds may be administered by the same or different route and the same or different method.
- a concomitant medicine comprising the compounds of the present invention and other drug may be administered as a combination preparation in which both components are contained in a single formulation or administered as separate formulations.
- the administration by separate formulations includes simultaneous administration and or administration of the formulations separated by some time intervals.
- the compound of the present invention can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present invention, so long as the two compounds are simultaneously active in the patient at least some of the time during the combination therapy.
- the administration method of the respective drugs may be administered by the same or different route and the same or different method.
- the dosage of the other drug can be properly selected, based on a dosage that has been clinically used, or may be a reduced dosage that is effective when administered in combination with a compound of the present invention.
- the compounding ratio of the compound of the present invention and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof.
- the other drug may be used in an amount of about 0.01 to about 100 parts by mass, based on 1 part by mass of the compound of the present invention.
- the other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion.
- the other drug that complements and/or enhances the therapeutic efficacy of the compound of the present invention includes not only those that have already been discovered, but those that will be discovered in future, based on the above mechanism.
- a compound of the invention may be administered with nonchemical methods of cancer treatment.
- a compound of the invention may be administered with radiation therapy.
- a compound of the invention may be administered with surgery, with thermoablation, with focused ultrasound therapy, with cryotherapy, or with any combination of these.
- the cancer is breast cancer.
- the cancer is metastatic breast cancer.
- the cancer is ER -positive, HR -positive or HER2-negative, advanced or metastatic breast cancer.
- the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
- the oral SERD is In some embodiments, the oral SERD is ZN-c5, D- 0502, or SHR9549, or a pharmaceutically acceptable salt thereof.
- the present invention provides methods for treating a breast cancer selected from the group consisting of hormone dependent breast cancer and hormone independent breast cancer. In some embodiments, the present invention provides methods wherein the breast cancer is metastatic. In some embodiments, the breast cancer is ER positive. In some embodiments, the breast cancer is HR positive. [0217] Head and neck cancer is a term used to define cancer that develops in the mouth, throat, larynx, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these cancers are squamous cell carcinomas, or cancers that begin in the lining of the mouth, nose and throat.
- HPV human papillomavirus
- cancers of the stomach are adenocarcinomas.
- a stomach cancer or gastric cancer almost always is an adenocarcinoma. These cancers develop from the cells that form the innermost lining of the stomach (the mucosa).
- NSCLC Non-small cell lung cancer
- SCC squamous cell carcinoma
- the present invention provides methods for treating cancer selected from head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, prostate cancer, soft-tissue sarcoma, adenocarcinoma, and lung cancer (e.g., non- small-cell lung cancer).
- cancer selected from head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, prostate cancer, soft-tissue sarcoma, adenocarcinoma, and lung cancer (e.g., non- small-cell lung cancer).
- Sarcomas, carcinomas, melanomas, and glioblastomas are the main types of solid malignant tumors.
- Sarcomas are tumors in a blood vessel, bone, fat tissue, ligament, lymph vessel, muscle or tendon.
- Carcinomas are tumors that form in epithelial cells. Epithelial cells are found in the skin, glands and the linings of organs.
- Melanomas are tumors that develop in the pigment-containing cells known as melanocytes.
- Glioblastoma is an aggressive cancer that begins in the brain. They can either start from normal brain cells or develop from an existing low-grade astrocytoma.
- a solid tumor grows in an anatomical site outside the bloodstream (in contrast, for example, to cancers of hematopoietic origin such as leukemias) and requires the formation of small blood vessels and capillaries to supply nutrients, etc. to the growing tumor mass.
- Non-limiting examples of solid malignant tumors include biliary cancer (e.g. , cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast), brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma, glioblastomas; medulloblastoma), cervical cancer (e.g., cervical adenocarcinoma), colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell
- liver cancer e.g., hepatocellular cancer (HCC), malignant hepatoma
- lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung), neuroblastoma, neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN)), prostate cancer (e.g., prostate adenocarcino
- the cancer is Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, Anal Cancer, Appendix Cancer, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Tumor, Astrocytoma, Brain and Spinal Cord Tumor, Brain Stem Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System Cancer, Cervical Cancer, Childhood Cancers, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer,
- ALL Acute Lympho
- the cancer is carcinomas of the breast, liver, lung, colon, kidney, bladder, small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate, skin, squamous cell carcinoma, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, B- cell lymphoma, T- cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma, Burkett's lymphoma, hematopoietic tumors of myeloid lineage, acute and chronic myelogenous leukemias, myelodysplastic syndrome, promyelocytic leukemia, tumors of mesenchymal origin,
- the cancer is selected from bladder cancer, breast cancer, esophageal cancer, gastric cancer, head & neck cancer, Kaposi’s sarcoma, lung cancer (including non-small cell lung cancer and small cell lung cancer), melanoma, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, testicular germ cell cancer, thymoma and thymic carcinoma.
- administering an oral SERD in combination with a compound of formula (I) provides improved efficacy relative to separately administering the compound of formula (I) or the oral SERD.
- administering an oral SERD in combination with a compound of formula (1) provides a synergistic effect.
- administering the oral SERD in combination with a compound of formula (I) provides improved efficacy for treating breast cancer relative to separately administering the compound of formula (I), or the oral SERD.
- administering the oral SERD in combination with a compound of formula (I) provides a synergistic effect in treating breast cancer.
- the compound of formula (I) and the oral SERD are administered simultaneously or sequentially.
- the oral SERD is administered within about 5 minutes to within about 168 hours prior to or after administration of the compound of formula (I).
- Step 2 Synthesis of tert-butyl 3-(2-(3-bromophenyl)-3-methylbutanamido)-5- cyclopropyl-lH-pyrazole-l-carboxylate
- Step 3 Synthesis of tert-butyl 5-cyclopropyl-3-(3-methyl-2-(3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)butanamido)-lH-pyrazole-l-carboxylate
- Step 4 Synthesis of (E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide
- Example 2 Combination Studies of Compound 44A (CPD-44A) and oral SERDs [0240] This example describes the evaluation of the effect of therapeutic test agents in human breast cancer cell lines (MCF7, T47D, and BT474) by Cell Titer Gio Cell Viability Analysis.
- This ex- vivo cell killing assay was conducted in a 384-well plate format (60 wells for test agent, plus 3 wells for vehicle control, and 3 wells for positive control), employing a 4-day incubation, and measuring ICso values with respect to Cell Titer Gio viability endpoints. Test articles in powder form were formulated in 100% DMSO. The Cell Titer Gio assay (Promega Cat# G7571) was conducted according to manufacturer instructions.
- Each cell group was a 12x8 combination matrix with duplicates per dose-point.
- Highest stock concentrations used for this study design were 60 mM for CPD-44A and 2 mM for Amcenestrant, Giredestrant, Camizestrant, and Elacestrant.
- Each cell group was a 12x8 combination matrix with duplicates per dose-point.
- Highest stocks used for this study design were 60 mM for CPD-44A and 2mM for Amcenestrant, Giredestrant, Camizestrant, Elacestrant.
- Human cancer cells for every tumor type were seeded in 40 pL of appropriate media in a 384-well plate on Day 0.
- Therapeutic agents to be tested were added to wells on Day 1 according to the experimental design using a Tecan D300e digital dispenser. 10% DMSO was used as a positive control; media + vehicle (0.2%DMSO) was used as negative control.
- DMSO was adjusted in all wells corresponding to the highest vehicle control across plates and study designs. Plates were incubated at 37°C with 5% CO2. Media was not changed during the 4-day incubation period with test agents. The highest concentration of DMSO across all plates, cell lines and study designs was 0.2%. On day 5, cell viability was tested using the Cell Titer Gio assay.
- Plates were removed from incubator and equilibrated to room temperature for up to 30 minutes. 20 pL of Cell Titer Gio reagent were added to wells and incubated at room temperature for 10 minutes to stabilize luminescent signal. Luminescence were recorded using a Tecan plate reader.
- Figs. 1 -4 show the matrices for the assay results for the test agents at the tested concentrations in the MCF7 cell line.
- the assay results in Figs. 1-12 are reported as a viability ratio. Lower ratios indicate lower cell viability at the tested concentrations as compared to negative control.
- Fig. 1 shows the matrix for CPD-44A + amcenestrant in the MCF7 cell line.
- Fig. 2 shows the matrix for CPD-44A + giredestrant in the MCF7 cell line.
- Fig. 3 shows the matrix for CPD-44A + camizestrant in the MCF7 cell line.
- Fig. 4 shows the matrix for CPD-44A + elacestrant in the MCF7 cell line.
- Figs. 5-8 show the matrices for the assay results for the test agents at the tested concentrations in the BT474 cell line.
- Fig. 5 shows the matrix for CPD-44A + amcenestrant in the BT474 cell line.
- Fig. 6 shows the matrix for CPD-44A + giredestrant in the BT474 cell line.
- Fig. 7 shows the matrix for CPD-44A + camizestrant in the BT474 cell line.
- Fig. 8 shows the matrix for CPD-44A + elacestrant in the BT474 cell line.
- Figs. 9-12 show the matrices for the assay results for the test agents at the tested concentrations in the T47D cell line.
- Fig. 9 shows the matrix for CPD-44A + amcenestrant in the T47D cell line.
- Fig. 10 shows the matrix for CPD-44A + giredestrant in the T47D cell line.
- Fig. 11 shows the matrix for CPD-44A + camizestrant in the T47D cell line.
- Fig. 12 shows the matrix for CPD-44A + elacestrant in the T47D cell line.
- mice Female, 7-8 week-old, NOD/SCID mice were purchased from GemPharmatech Co., and acclimated in the laboratory 1 week before experimentation. The animals were housed in microisolator cages, five per cage, in a 12-h light/dark cycle. The animals received filtered sterilized water and sterile rodent food ad libitum. The animals were observed daily, and clinical signs were noted. Each mouse was inoculated orthotopically at the right mammary fat pad region with MCF7 tumor cells (2 x 10 7 ) in 0.2 ml of PBS mixed with Matrigel (1:1) for tumor development.
- CPD-44A Animals were treated with CPD-44A orally once daily for a total of 28 days.
- CPD- 44A is formulated in 0.5% Tween 80 + 0.5% methyl cellulose.
- Fulvestrant injection solution purchased from AstraZeneca, was administered s.c. once weekly for the duration of study.
- Elacestrant purchased from MedChemExpress, was formulated in 5% DMSO/40%PEG400/5% Tween/50% saline, and administered orally once daily for the duration of study.
- Compounds were administered by exact body weight, with the administered volume being 1 Opl/ g body weight.
- Tumors were measured and the animals weighed twice weekly. Tumor volume was determined by caliper measurements (mm) and using the formula for an ellipsoid sphere: L x W 2 /2 mm3 . As shown in Figure 17, the combination of CPD-44A and elacestrant was found to be more effective in reducing tumor growth than either agent alone.
- Exemplary embodiments according to the present disclosure include, but are not limited to, those recited in the appended claims and the following embodiments.
- a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with a therapeutically effective amount of an oral selective estrogen receptor degrader (SERD); wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heteroaryl, heterocyclyl or absent;
- SESD selective estrogen receptor degrader
- Ri is hydrogen or alkyl
- R2 is hydrogen, alkyl or cycloalkyl
- R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R 5 is:
- R 5 ' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)i-3-NR a Rb,
- R5" is H or alkyl
- Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl, or alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S, wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
- Re at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- Li is *-CRcRd-C(O)-, *-NReC(O)- or absent, wherein * is the point of attachment with ring A;
- Rc and Rd independently are hydrogen, alkyl or haloalkyl, or alternatively, Rc and Ra together with the carbon to which they are attached form a cycloalkyl ring;
- Re is hydrogen or alkyl
- L2 is -C(O)NH- -C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
- R 5 is: wherein R a and Rb are each independently hydrogen or alkyl, or alternatively,
- R a and Rb together with the nitrogen atom to which they are attached form the optionally substituted ring, wherein the optional substituent is independently one or more halo, alkyl, hydroxy, haloalkyl or alkoxy.
- ring B is cycloalkyl, aryl, heterocycloalkyl or heteroaryl, each of which is monocyclic or bicyclic.
- a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of (5)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of an oral SERD.
Abstract
The present invention provides a combination of a substituted heterocyclyl derivative of formula (I) or a pharmaceutically acceptable salt thereof which is a CDK7 inhibitor along with an oral selective estrogen receptor degrader (SERD), and a method of treating cancer in a subject, comprising administering to the subject a compound of formula (I) in combination with the oral SERD.
Description
CANCER THERAPY USING A COMBINATION OF A CDK7 INHIBITOR WITH AN ORAL SERD
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application claims priority to and benefit of U.S. Provisional Pat. Appl. No. 63/342,470, filed on May 16, 2022, which application is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention pertains to methods for treating cancer in a subject, comprising administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with an oral selective estrogen receptor degrader (SERD).
BACKGROUND
[0003] Cyclin-dependent kinase (CDK7) is necessary for transcription and acts by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (PolII) to enable transcription initiation. CDK7 also modulates regulated gene expression by phosphorylating transcription factors, including p53, retinoid receptors, androgen receptor, and estrogen receptor. Ligand-dependent phosphorylation of serine 118 (Seri 18), important for ERa function and turnover, is mediated by CDK7 (Oncogene; 2002; 21:4921). Hence pharmacological modulation of CDK7 kinase activity is considered to be an important approach to treat cancers that are critically dependent on transcription to maintain their oncogenic state. CDK7, which complexes with cyclin H and MAT1, phosphorylates the cell cycle CDKs in the activation of T-loop, to promote their activities (Fisher et al., Cell., Aug 26;78(4):713-24, 1994). Recent genetic and biochemical studies have confirmed the importance of CDK7 for cell cycle progression (Larochelle et al., Mol Cell., Mar 23;25(6):839-50. 2007; Ganuza et al., EMBO J., May 30; 31(11): 2498-510, 2012).
[0004] Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed. Given the dependence on active ER signaling in these tumors, the predominant treatment strategy has been to inhibit various aspects of this pathway including directly antagonizing ER, for example with selective estrogen receptor degraders (SERDs).
Interestingly, the dependence on ER for breast cancer growth is often retained even after progression through several lines of antiestrogen therapy, making ER a bona fide biomarker for this cancer subtype and driving the continued research and development of novel ER- targeted therapeutics to treat this patient population. This, combined with the continuous discovery of mechanisms underlying endocrine resistance, is resulting in a continually evolving treatment landscape for ER+ breast cancer. Oral SERDs, having SERD activity with good oral bioavailability, are being developed to allow for convenient oral administration for treatment of cancers, including ER+ breast cancer. Oral SERDs are also being investigated in other cancers such as ovarian cancer and endometrial cancer.
[0005] In recent times, promising drug targets have been identified for their effective use in the cancer treatment. These chemotherapies are effective in certain types of cancer; but their effectiveness has always been restricted due to drug resistance and side effects on normal tissues and cells. The development of multidrug resistance to chemotherapy remains a major challenge in treating cancer. Therefore, the continual advancement of novel anticancer therapy remains to be a prime public health demand, despite of the present available anticancer drugs in the market.
SUMMARY
[0006] The present invention provides methods and compositions for treating cancer using a compound of formula (I) or a pharmaceutically acceptable salt thereof, including combination therapy with an oral selective estrogen receptor degrader (SERD).
[0007] Provided herein is a method of treating cancer in a subject, comprising administering to the subject a compound of formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;
ring B is aryl, cycloalkyl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
R2 is hydrogen, alkyl or cycloalkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
or wherein R5' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)I-3-
NRaRb; R5" is H or alkyl;
Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl ; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
R6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
L1 is *-CRcRd -C(O)-, *-NReC(O)- or absent; wherein * is the point of attachment with ring A;
Rc and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon atom to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is -C(O)NH-, — C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1 ; and q is 0 to 3.
[0008] In some embodiments, disclosed herein is a use of a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with an oral SERD for the treatment of cancer.
[0009] In some embodiments, disclosed herein is a use of a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, including combinations thereof in all ratios, as a medicament for treating cancer in combination with an oral SERD.
[0010] In some embodiments, the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
[0011] In some embodiments, the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
[0012] In some embodiments, the cancer is breast cancer.
[0013] In some embodiments, the cancer is metastatic breast cancer.
[0014] In some embodiments, the cancer is metastatic hormone resistant breast cancer.
[0015] In some embodiments, the cancer is ER-positive (estrogen receptor positive), HRpositive (hormone receptor positive, i. c. , ER-positive and progesterone receptor (PR)- positive) or HER2 -negative (human epidermal growth factor receptor 2 negative), advanced or metastatic breast cancer.
[0016] In some embodiments, the cancer is non-small cell lung cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Fig. 1 is a cell viability matrix for CPD-44A + amcenestrant in a MCF7 cell line.
[0018] Fig. 2 is a cell viability matrix for CPD-44A + giredestrant in a MCF7 cell line.
[0019] Fig. 3 is a cell viability matrix for CPD-44A + camizestrant in a MCF7 cell line.
[0020] Fig. 4 is a cell viability matrix for CPD-44A + elacestrant in a MCF7 cell line.
[0021] Fig. 5 is a cell viability matrix for CPD-44A + amcenestrant in a BT474 cell line.
[0022] Fig. 6 is a cell viability matrix for CPD-44A + giredestrant in a BT474 cell line.
[0023] Fig. 7 is a cell viability matrix for CPD-44A + camizestrant in a BT474 cell line.
[0024] Fig. 8 is a cell viability matrix for CPD-44A + elacestrant in a BT474 cell line.
[0025] Fig. 9 is a cell viability matrix for CPD-44A + amcenestrant in a T47D cell line.
[0026] Fig. 10 is a cell viability matrix for CPD-44A + giredestrant in a T47D cell line.
[0027] Fig. 11 is a cell viability matrix for CPD-44A + camizestrant in a T47D cell line.
[0028] Fig. 12 is a cell viability matrix for CPD-44A + elacestrant in a T47D cell line.
[0029] Fig. 13 is a Loewe synergy score matrix for CPD-44A + amcenestrant in a MCF7 cell line.
[0030] Fig. 14 is a Loewe synergy score matrix for CPD-44A + elacestrant in a MCF7 cell line.
[0031] Fig. 15 is a Loewe synergy score matrix for CPD-44A + giredestrant in a MCF7 cell line.
[0032] Fig. 16 is a Loewe synergy score matrix for CPD-44A + camizestrant in a MCF7 cell line.
[0033] Fig. 17 is a plot of median tumor volume in a MCF7 mouse xenograft model following dosing of CPD-44A, elacestrant, or a combination thereof.
DETAILED DESCRIPTION
[0034] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one skilled in the art to which the subject matter herein belongs. As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated to facilitate the understanding of the present invention.
[0035] As used herein, unless otherwise defined the term “alkyl” alone or in combination with other term(s) means saturated aliphatic hydrocarbon chains, including Ci-Cio straight or C3-C10 branched alkyl groups. Examples of “alkyl” include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl and the like.
[0036] As used herein, the term “halo” or “halogen” alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
[0037] As used herein, the term “haloalkyl” means alkyl substituted with one or more halogen atoms independently, wherein the alkyl groups are as defined above. The term “halo” is used herein interchangeably with the term “halogen” means F, Cl, Br or I. Examples of
“haloalkyl” include but are not limited to fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
[0038] As used herein, the term “hydroxy” or “hydroxyl” alone or in combination with other term(s) means -OH.
[0039] As used herein, the term “alkoxy” refers to the group alkyl-O- or -O-alkyl, where alkyl groups are as defined above. Exemplary alkoxy- groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy and the like. An alkoxy group can be unsubstituted or substituted independently with one or more suitable groups.
[0040] As used herein, the term “alkoxyalkyl” refers to the group alkyl-O-alkyl-, wherein alkyl and alkoxy groups are as defined above. Exemplary alkoxyalkyl- groups include but are not limited to methoxymethyl, ethoxymethyl, methoxyethyl, isopropoxymethyl and the like.
[0041] As used herein, the term “cyano” refers to -CN; and the term “cyanoalkyl” refers to alkyl substituted with -CN; wherein the alkyl groups are as defined above.
[0042] As used herein, the term “amino” refers to -NH2;
[0043] As used herein, the term “nitro” refers to -NO2;
[0044] As used herein, the term “acyl” refers to the group -C(O)-alkyl, wherein alkyl groups are as defined above. Exemplary acyl- groups include but are not limited to acetyl, propanoyl and acrylyl. An acyl group can be unsubstituted or substituted independently with one or more suitable groups.
[0045] As used herein the term “cycloalkyl” alone or in combination with other term(s) means C3-C10 saturated cyclic hydrocarbon ring. A cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused and spirocyclyls and the like.
[0046] As used herein, the term “aryl” is optionally substituted monocyclic, bicyclic or polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms. Examples of a C6-C14 aryl group include, but are not limited to phenyl, naphthyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl. An aryl group can be unsubstituted or substituted independently with one or more suitable groups.
[0047] The term “heterocycloalkyl” refers to a non-aromatic, saturated or partially saturated monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or hetero group selected from O, N, S, S(O), S(O)2, NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur. A monocyclic heterocycloalkyl may typically contain 4 to 7 ring atoms. Examples of “heterocycloalkyl” include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl and N-oxides thereof. Attachment of a heterocycloalkyl substituent can occur via either a carbon atom or a heteroatom. A heterocycloalkyl group can be optionally independently substituted with one or more suitable groups selected from one or more aforesaid groups.
[0048] As used herein, the term “heteroaryl” alone or in combination with other term(s) means a completely unsaturated ring system containing a total of 5 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms/groups being independently selected from the group consisting of carbon, oxygen, nitrogen or sulfur. A heteroaryl may be a single-ring (monocyclic) or polycyclic ring system. Examples of “heteroaryl” include but are not limited to pyridyl, indolyl, benzimidazolyl, benzothiazolyl and the like.
[0049] As used herein, the term “heterocyclyl” alone or in combination with other term(s) includes both “heterocycloalkyl” and “heteroaryl” groups which are as defined above.
[0050] The term “heteroatom” as used herein designates a sulfur, nitrogen or oxygen atom.
[0051] As used in the above definitions, the term “optionally substituted” or “substituted” or “optionally substituted with suitable groups” refers to replacement of one or more hydrogen radicals in a given structure with a radical of a specified substituent including, but not limited to halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic
acid, sulfonyl, phosphonic acid, aryl and heteroaryl. It is understood that the substituent may be further substituted.
[0052] As used herein, the term “comprise” or “comprising” is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
[0053] As used herein, the term “or” means “and/or” unless stated otherwise.
[0054] As used herein, the term “including” as well as other forms, such as “include", “includes” and “included” is not limiting.
[0055] The term “treatment”/“treating” means any treatment of a disease in a mammal, including (a) Inhibiting the disease, i.e., slowing or arresting the development of clinical symptoms; and/or (b) Relieving the disease, i.e., causing the regression of clinical symptoms and/or (c) Alleviating or abrogating a disease and/or its attendant symptoms.
[0056] "Pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
[0057] The term “pharmaceutically acceptable salt” refers to a product obtained by reaction of the compound of the present invention with a suitable acid or a base. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Al, Zn and Mn salts. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic/organic acids such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, 4-methylbenzenesulfonate or p-toluenesulfonate salts, and the like. Certain compounds of the invention (can form pharmaceutically acceptable salts with various organic bases such as lysine, arginine, guanidine, diethanolamine or metformin. Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc, salts.
[0058] The term “stereoisomers” refers to any enantiomers, diastereomers, or geometrical isomers of the compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG), wherever
they are chiral or when they bear one or more double bonds. When the compounds of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG) are chiral, they can exist in racemic or in optically active form. The invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric and epimeric forms, as well as tZ-isomers and l- isomers and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all cis/trans, syn/anti, entgegen (E) / zusammen (Z), (R)/(S) isomers as well as the appropriate mixtures thereof.
[0059] In some embodiments, the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2H (“D”), 3H, nC, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36C1, 123I and 125I. Isotopically labeled compounds of the present inventions can generally be prepared by following procedures well known in the art, such as by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0060] As used herein, the term “subject” refers to an animal, preferably a mammal, and most preferably a human.
[0061] As used herein, the term, “therapeutically effective amount” refers to an amount of a compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer
thereof; or a composition comprising the compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer thereof, effective in producing the desired therapeutic response in a particular patient suffering from cancer. Particularly, the term “therapeutically effective amount” includes the amount of the compound of the present invention or a pharmaceutically acceptable salt or a stereoisomer thereof, when administered, that induces a positive modification in the disease or disorder to be treated or is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease or disorder being treated in a subject. In respect of the therapeutic amount of the compound, the amount of the compound used for the treatment of a subject is low enough to avoid undue or severe side effects, within the scope of sound medical judgment can also be considered. The therapeutically effective amount of the compound or composition will be varied with the condition being treated, the severity of the condition being treated, the duration of the treatment, the nature of concurrent therapy, the age and physical condition of the end user, the specific compound or composition employed the particular pharmaceutically acceptable carrier utilized.
[0062] As used herein, the term, “oral SERD” refers to a therapeutic compound that possesses biological activity as a selective estrogen receptor degrader and has adequate oral bioavailability to be suitable for oral administration. For example, an oral SERD has oral bioavailability that is greater than SERDs that are not suitable for oral administration due to their poor oral bioavailability (e.g., fulvestrant).
[0063] In some embodiments, compounds of the invention may be used in combination with another therapeutic agent. As used herein, administering a first agent (e.g., a compound of formula (I)) in combination with a second agent (e.g., an oral SERD) refers to any form of administration of two or more different therapeutic compounds such that the second agent is administered while the first agent is still effective in the body (e.g., the two compounds are simultaneously effective in the subject, which may include synergistic effects of the two compounds). For example, the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially. In some embodiments, the different therapeutic compounds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. In some embodiments, the second agent is administered within about 5 minutes to within about 168 hours prior to or after administration of the first agent. Thus, a subject who receives such treatment can benefit from a combined effect of the administered therapeutic compounds.
[0064] In some embodiments, the present invention provides methods wherein an oral SERD is administered within about 5 minutes to within about 168 hours prior to or after administration of a compound of formula (I). In some embodiments, the present invention provides methods wherein an oral SERD is administered within 0.5 hours to 72 hours prior to or after administration of a compound of formula (I). In some embodiments, the present invention provides methods wherein an oral SERD is administered within 0.5 hours to 24 hours prior to or after administration of a compound of formula (I). In some embodiments, the present invention provides methods wherein an oral SERD is administered within 2 hours prior to or after administration of a compound of formula (I).
[0065] In some embodiments, the present invention provides methods comprising administering a compound of formula (I) prior to administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (1) 2 hours prior to administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) within 0.5 hours to 72 hours after administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) about 2 hours after administering an oral SERD. In some embodiments, the present invention provides methods comprising administering a compound of formula (I) at least 1 hour after an oral SERD.
[0066] In some embodiments, combination therapy of compounds of the invention with one or more additional therapeutic agent(s) (e.g., one or more additional chemotherapeutic agent(s)) provide improved efficacy relative to each individual administration of the compound of the invention or the one or more additional therapeutic agent(s). In certain such embodiments, the combination therapy provides an additive effect, wherein an additive effect refers to the sum of each of the effects of individual administration of the compound of the invention and the one or more additional therapeutic agent(s).
[0067] Provided herein is a method of treating cancer in a subject, comprising administering to the subject a compound of formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
R2 is hydrogen, alkyl or cycloalkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
O ; wherein R5 is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)i-3- NRaRb; R5" is H or alkyl;
Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
R5 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
Li is *-CRcRd-C(O)-, *- -NReC(O)- or absent; wherein * is the point of attachment with ring A;
Rc and Ri independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is -C(O)NH- — C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
[0068] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (IA):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
R2 is hydrogen, alkyl or cycloalkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
R4 at each occurrence is halo, alkyl, hydroxy or alkoxy;
; wnerem KS IS nyarogen, naio, aiKyi, aiKoxy, aiKoxyaucyi or - (CH2)i-3-NRaRb; R5" is H or alkyl;
Ra and Rb are each independently hydrogen or alkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0- 2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
Li is *-CRcRd-C(O)-, *-NReC(O)- or absent; wherein * is the point of attachment with ring A;
Rc and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon atom to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is -C(O)NH-, -C(O)O- or absent;
m is 0, 1 or 2; and p is 0 or 1.
[0069] In some embodiments, the present methods include administering a compound of formula (1) represented by formula (IB):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
[0070] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (IC):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
[0071] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (ID):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof. [0072] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (IE):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Li is ; and wherein * is the point of attachment with
phenyl ring.
[0073] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (IF):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Li is and wherein * is the point of attachment with
phenyl ring.
[0074] In some embodiments, the present methods include administering a compound of formula (I) represented by formula (IG):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
[0075] In some embodiments, provided herein is a method of treating breast cancer in a subject, comprising administering to the subject a compound of formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with an oral SERD; wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
R2 is hydrogen, alkyl or cycloalkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
or
wherein R5' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)I-3- NRaRb; R5" is H or alkyl;
Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
R5 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
Li is *-CRcR<i-C(O)-, *-NR«C(O)- or absent; wherein * is the point of attachment with ring A;
Rc and Ri independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is -C(O)NH-, -C(0)0- or absent; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
[0076] In some embodiments, the present methods include administering a compound of formula (I) wherein ring A is aryl or heteroaryl.
[0077] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is aryl.
[0078] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is 1,3-phenylene.
[0079] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is monocyclic or bicyclic, cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
[0080] In some embodiments, the present methods include administering compounds of formula (I), wherein ring B is aryl. Preferably the aryl is phenyl.
[0081] In some embodiments, the present methods include administering compounds of formula (I), wherein ring B is heterocyclyl. Preferably the heterocyclyl is piperidinyl, pyridinyl, piperazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
[0082] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is cycloalkyl.
[0083] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
[0084] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5' is -(CH2)i-3-NRaRb.
[0085] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ra and Rb together with the
nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N.
[0086] In some embodiments, the present methods include administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein Li is *-CRcRd-C(O)-; wherein * is the point of attachment with ring A.
[0087] According to the preceding embodiment, specifically provided are methods which include administering a compound of formula (I), wherein Rc and Rd are independently hydrogen or alkyl, wherein the alkyl is methyl, ethyl or isopropyl.
[0088] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein L2 is absent.
[0089] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein when Li is present, L2 is absent.
[0090] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is alkyl or cycloalkyl. Preferably the alkyl is ethyl and the cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
[0091] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen and alkyl; wherein the alkyl is methyl.
[0092] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R4 is halo. Preferably the halo is fluoro.
[0093] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein R5' is hydrogen or -CH2-NRaRb.
[0094] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
when R5 is attached to hetero atom of ring B; R5' is hydrogen or -CH2-NRaRb.
[0095] According to the preceding two embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the Ra and Rb are each independently hydrogen or alkyl. Preferably the alkyl is methyl.
[0096] According to the preceding embodiment, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, hydroxy, haloalkyl or alkoxy.
[0097] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is meta-substituted with respect to Li and L2.
[0098] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is monocyclic or bicyclic, cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
[0099] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring B is heterocyclyl. In another embodiment, the heterocyclyl is piperidinyl, pyridinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
[0100] In some embodiments, the present methods include administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
[0101] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein m is 1.
[0102] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.
[0103] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 1.
[0104] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 is cycloalkyl; in another embodiment, the cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
[0105] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and Ri together with the atoms to which they are attached form a 5 or 6 membered ring.
[0106] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and R3 together with the atoms to which they are attached form a 5 or 6 membered ring.
[0107] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R2 and R3 together with the atoms to which they are attached form a 6 membered aromatic ring.
[0108] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein R5' is hydrogen, halo, alkyl, alkoxy or alkoxyalkyl; and R5" is H or alkyl.
[0109] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein R5' is -CH2-NRaRb; R5" is H or alkyl; Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl.
[0110] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein R5' is -CH2-NRaRb; R5" is H or alkyl; Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted 4-7 membered heterocyclyl ring
containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl.
[0111] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein p is 1 , Ra and Rb are as defined in formula (I).
[0112] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5 is:
wherein '- is a point of attachment.
[0113] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R5' is -(CH2)i-3-NRaRb; wherein Ra and Rb are as defined in formula (I).
[0114] In some embodiments, the present methods include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein when Li is -CRcRa-C(O)- or -NReC(O)-, L2 is absent.
[0115] In some embodiments, the present methods include administering a compound of formula (I) selected from Table 1 below:
[0116] In some embodiments, the compound of formula (I) is selected from:
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-((S)-3-fluoropyrrolidin-l-yl)but-2-enamide;
N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-l-oxopropan-2-yl)phenyl)pyridin-2- yl)acrylamide;
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5-(3-(l -((5-cyclopropyl-l H-pyrazol-3-yl)amino)-l -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-morpholinobut-2-enamide ;
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-(pyrrolidin- 1 -yl)but-2-enamide;
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide;
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phcnyl)pyridin-2- yl)-4-(piperidin- 1 -yl)but-2-enamide;
(E)-N -(3 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2-yl)-3 -fluoro-
[l,r-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; and
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-(3-fluoropiperidin- 1 -yl)but-2-enamide.
[0117] In certain preceding embodiments, the compound of formula (I) is selected from:
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-(pyrrolidin- 1 -yl)but-2-enamide; and
(E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2-yl)phenyl)pyridin-2- yl)-4-morpholinobut-2-enamide.
[0118] In some embodiments, the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0119] In some embodiments, the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (.S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)aniino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0120] In some embodiments, the present methods include administering a compound of formula (I), wherein the compound of formula (I) is (7?)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0121] In some embodiments, the present methods include administering a compound of formula (I) in combination with an oral SERD selected from elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
[0122] In some embodiments, the oral SERD is elacestrant or a pharmaceutically acceptable salt thereof.
[0123] In some embodiments, the oral SERD is rintodestrant or a pharmaceutically acceptable salt thereof.
[0124] In some embodiments, the oral SERD is giredestrant or a pharmaceutically acceptable salt thereof.
[0125] In some embodiments, the oral SERD is amcenestrant or a pharmaceutically acceptable salt thereof.
[0126] In some embodiments, the oral SERD is camizestrant or a pharmaceutically acceptable salt thereof.
[0127] In some embodiments, the oral SERD is imlunestrant or a pharmaceutically acceptable salt thereof.
[0128] In some embodiments, the oral SERD is LSZ-102 or a pharmaceutically acceptable salt thereof.
[0129] In some embodiments, the oral SERD is ZN-c5, D-0502, or SHR9549, or a pharmaceutically acceptable salt thereof.
[0130] In some embodiments, compound of formula (I) is compound 44A (“CPD-44A”) of Table 1, which is (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide. The structure of compound 44A is shown below:
Compound 44A and crystalline forms thereof are described in PCT Publication No. WO 2022/130304 Al, published June 23, 2022, the entire contents of which are incorporated herein by reference. Processes for preparing Compound 44A are described in PCT Publication NO. WO 2022/229835 Al, published November 3, 2022, the entire contents of which are incorporated herein by reference.
[0131] In some embodiments, compound of formula (I) is a CDK7 inhibitor.
[0132] In some embodiments, the present methods include administering a compound of formula (I) in combination with an oral SERD, wherein the combination therapy provides a synergistic effect.
[0133] In some embodiments, the compound of formula (I) and the oral SERD are administered simultaneously or sequentially.
[0134] In some embodiments, the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
[0135] In some embodiments, the cancer is breast cancer.
[0136] In some embodiments, the cancer is metastatic breast cancer.
[0137] In some embodiments, the cancer is ER-positive, HR-positive or HER2 -negative, advanced or metastatic breast cancer.
[0138] In some embodiments, the cancer is ER-positive breast cancer. In some embodiments, the cancer may be characterized by one or more mutations in estrogen receptor 1 (ESRI) that confer estrogen-independent ER activation and resistance to certain therapies such as aromatase inhibitors. Examples of such mutations include ligand binding domain mutations such as D538G, Y537S, Y537N, Y537C, L536H, L536P, L536R, S463P, and E380Q. See, Brett, et al. Breast Cancer Res 23, 85 (2021), which is incorporated herein by reference in its entirety. In some embodiments, the ER-positive breast cancer is characterized by a wild-type ER (e.g., wild-type ESRI).
[0139] In some embodiments, the cancer is HR-positive breast cancer, i.e., the cancer is ER-positive and progesterone receptor (PR)-positive.
[0140] In some embodiments, the cancer is non-small cell lung cancer.
[0141] In some embodiments, the cancer is ER-positive ovarian cancer.
[0142] In some embodiments, the cancer is ER-positive epithelial cancer.
[0143] In some embodiments, the cancer is epithelial ovarian cancer.
[0144] In some embodiments, the cancer is triple negative breast cancer.
[0145] Tn some embodiments, and cancer is metastatic castration-resistant prostate cancer.
[0146] In some embodiments, the present invention provides a pharmaceutical composition comprising an oral SERD, a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
[0147] In some embodiments, the present invention provides a method of treating breast cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of (<S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide or a pharmaceutically acceptable salt thereof in combination with an oral SERD.
[0148] According to some further examples of the preceding embodiment, the breast cancer is ER-positive, HR-positive or HER2 -negative, advanced or metastatic breast cancer.
[0149] In some embodiments, the present methods comprise administering a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof. In some embodiments, the therapeutically effective amount of a compound of formula (I) is a total daily dosage of from about 5 mg to about 500 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I) is a total daily dosage of from about 10 mg to about 250 mg. In some embodiments, the total daily dosage is from about 20 mg to about 160 mg. In some embodiments, the total daily dosage is from about 20 mg to about 80 mg. In some embodiments, the total daily dosage is from about 20 mg to about 40 mg. In some embodiments, the total daily dosage is from about 40 mg to about 160 mg. In some embodiments, the total daily dosage is from about 40 mg to about 80 mg. In some embodiments, the total daily dosage is from about 80 mg to about 160 mg. In some embodiments, the total daily dosage is about 20 mg, about 40 mg, about 80 mg, or about 160 mg.
[0150] In some embodiments, the present methods comprise administering a therapeutically effective amount of compound 44A or a pharmaceutically acceptable salt or a stereoisomer thereof. In some embodiments, the therapeutically effective amount of Compound 44A or a pharmaceutically acceptable salt thereof is a total daily dosage of from about 5 mg to about 500 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 10 mg to about 250 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 80 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 20 mg to about 40 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 40 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 40 mg to about 80 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is from about 80 mg to about 160 mg. In some embodiments, the total daily dosage of Compound 44A or a pharmaceutically acceptable salt thereof is about 20 mg, about 40 mg, about 80 mg, or about 160 mg.
[0151] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof (e.g., Compound 44A or a pharmaceutically
acceptable salt thereof) is administered orally. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof (e.g., Compound 44A or a pharmaceutically acceptable salt thereof) is administered once daily. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof (e.g., Compound 44A or a pharmaceutically acceptable salt thereof) is administered twice daily. In some embodiments, the total dose of the compound of formula (I) (e.g., Compound 44-A) or a pharmaceutically acceptable salt (e.g., Compound 44-A fumarate) or a stereoisomer thereof is from about 60 mg to about 100 mg, administered in two separate administrations per day, e.g., from about 30 mg to about 50 mg twice daily (BID). In some embodiments, the total dose of the compound or pharmaceutically acceptable salt (e.g., Compound 44-A fumarate) is 80 mg, administered in two separate administrations per day, e.g., 40 mg twice day (BID).
[0152] In some embodiments, the present methods comprise administering a therapeutically effective amount of an oral SERD.
[0153] In some embodiments, the present methods comprise administering a therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof. Elacestrant, compositions thereof, and methods of use thereof, are described in U.S. Patent Nos. 7,612,114; 8,399,520; 10,071,066; 10,385,008; 10,420,734; and 10,745,343, the entire contents of each of which are incorporated herein by reference. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 500 mg, e.g., about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 500 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 250 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 100 mg. In some embodiments, the therapeutically effective amount of elacestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, elacestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0154] In some embodiments, the present methods comprise administering a therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 1,000 mg, e.g., about 50 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1,000 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 200 mg to about 1,000 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 500 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, the therapeutically effective amount of rintodestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 300 mg. In some embodiments, rintodestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0155] In some embodiments, the present methods comprise administering a therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 50 mg, e.g., about 1 mg, about 2 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, or about 50 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 5 mg to about 50 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 25 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 1 mg to about 10 mg. In some embodiments, the therapeutically effective amount of giredestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 20 mg. In some embodiments, giredestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0156] In some embodiments, the present methods comprise administering a therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of amcenestrant or a
pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 400 mg, e.g., about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, or about 400 mg. In some embodiments, the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 400 mg. In some embodiments, the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 200 mg. In some embodiments, the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 100 mg. In some embodiments, the therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 20 mg to about 200 mg. In some embodiments, amcenestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0157] In some embodiments, the present methods comprise administering a therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 100 mg, e.g., about 2 mg, about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 75 mg, or about 100 mg. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 10 mg to about 100 mg. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 50 mg. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 2 mg to about 25 mg. In some embodiments, the therapeutically effective amount of camizestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 5 mg to about 50 mg. In some embodiments, camizestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0158] In some embodiments, the present methods comprise administering a therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 500 mg, e.g., about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, or about 500 mg. In some embodiments, the therapeutically effective amount of
imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 500 mg. In some embodiments, the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 250 mg. In some embodiments, the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 25 mg to about 100 mg. In some embodiments, the therapeutically effective amount of imlunestrant or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, imlunestrant or a pharmaceutically acceptable salt thereof is administered once daily.
[0159] In some embodiments, the present methods comprise administering a therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 900 mg, e.g., about 50 mg, about 100 mg, about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 900 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 200 mg to about 900 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 500 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 50 mg to about 200 mg. In some embodiments, the therapeutically effective amount of LSZ-102 or a pharmaceutically acceptable salt thereof is a total daily dose of from about 100 mg to about 300 mg. In some embodiments, LSZ-102 or a pharmaceutically acceptable salt thereof is administered once daily.
[0160] In some embodiments, COMPOUND 44A is in the form of a salt or cocrystal of COMPOUND 44A. In some embodiments, COMPOUND 44A is in the form of a salt. In some embodiments, the salt is crystalline. In some embodiments, COMPOUND 44A is in the form of a cocrystal. In some embodiments, COMPOUND 44A is in the form of a fumaric acid salt or cocrystal. In some embodiments, the fumaric acid salt is crystalline. In some embodiments, COMPOUND 44A fumarate is a cocrystal of crystalline Form 1, as described in WO 2022/130304 AL In some embodiments, the molar ratio of COMPOUND A to fumaric acid is 1 : 1. In some embodiments, the COMPOUND 44A fumarate is anhydrous. In
some embodiments, the salt or cocrystal comprises greater than or equal to 98 wt% of COMPOUND A fumarate by weight of the salt or cocrystal.
Pharmaceutical compositions
[0161] In some embodiments, the present methods include a pharmaceutical composition comprising one or more of the compounds as disclosed herein, optionally admixed with a pharmaceutically acceptable carrier or diluent.
[0162] The pharmaceutical composition(s) of the present invention can be administered orally, for example in the form of tablets, coated tablets, pills, capsules, granules or elixirs. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injectable sterile solutions or suspensions, or topically, for example in the form of ointments or creams or transdermals, in the form of patches, or in other ways, for example in the form of aerosols or nasal sprays. An oral SERD is administered orally and formulated for oral administration.
[0163] The pharmaceutical composition(s) usually contain(s) about 1% to 99%, for example, about 5% to 75%, or from about 10% to about 30% by weight of the compound of formula (I) or pharmaceutically acceptable salts thereof. The amount of the compound of formula (I) or pharmaceutically acceptable salts thereof in the pharmaceutical composition(s) can range from about 1 mg to about 500 mg or from about 2.5 mg to about 250 mg or from about 5 mg to about 50 mg.
[0164] The present invention also provides methods for formulating the disclosed compounds as for pharmaceutical administration.
[0165] The compositions and methods of the present invention may be utilized to treat an individual in need thereof. In some embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an individual, such as a human, the composition or the compound is preferably administered as a pharmaceutical composition comprising, for example, a compound of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters.
[0166] In a preferred embodiment, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen- free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as an eye drop.
[0167] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the invention. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation of pharmaceutical composition can be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the invention. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
[0168] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols,
such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
[0169] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); anally, rectally or vaginally (for example, as a pessary, cream or foam); parenterally (including intramuscularly, intravenously, subcutaneously or intrathecally as, for example, a sterile solution or suspension); nasally; intraperitoneally; subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin, or as an eye drop). The compound may also be formulated for inhalation. In some embodiments, a compound may be simply dissolved or suspended in sterile water.
[0170] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
[0171] In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 50% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 60% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 70% by weight of the composition. In some embodiments, the pharmaceutical composition
comprises the active ingredient in an amount of at least about 80% by weight of the composition. In some embodiments, the pharmaceutical composition comprises the active ingredient in an amount of at least about 90% by weight of the composition.
[0172] In some embodiments, the oral pharmaceutical composition comprising the active ingredient of the present invention is a unit dose composition.
[0173] In some embodiments, the active ingredient is a compound of formula (I).
[0174] In some embodiments, the active ingredient is selected from: (E)-N-(5-(3-(l-((5- cyclopropyl- 1 H-pyrazol-3-yl)amino)-3-methyl- 1 -oxobutan-2-yl)phenyl)pyri din-2 -yl)-4- morpholinobut-2-enamide; (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 - oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-l-yl)but-2-enamide; and (E)-N-(5-(3-(l- ((5-cyclopropyl-lH-pyrazol-3-yl)amino)-l-oxopropan-2-yl)phenyl)pyridin-2-yl)-4- morpholinobut-2-enamide.
[0175] In some embodiments, the active ingredient is (E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0176] In some embodiments, the active ingredient is (1S)-(E)-N-(5-(3-(l-((5-cyclopropyl- lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0177] In some embodiments, the active ingredient is (7?)-(E)-N-(5-(3-(l-((5-cyclopropyl- lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide.
[0178] Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0179] Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-
water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. Compositions or compounds may also be administered as a bolus, electuary or paste.
[0180] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0181] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0182] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and
other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro- encapsulated form, if appropriate, with one or more of the above-described excipients.
[0183] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0184] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0185] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0186] Formulations of the pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as a suppository, which may be prepared by mixing one or more active compounds with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate,
and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[0187] Formulations of the pharmaceutical compositions for administration to the mouth may be presented as a mouthwash, or an oral spray, or an oral ointment.
[0188] Alternatively, or additionally, compositions can be formulated for delivery via a catheter, stent, wire, or other intraluminal device. Delivery via such devices may be especially useful for delivery to the bladder, urethra, ureter, rectum, or intestine.
[0189] Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[0190] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
[0191] The ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0192] Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0193] Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
[0194] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Exemplary ophthalmic formulations
are described in U.S. Publication Nos. 2005/0080056, 2005/0059744 and U.S. Pat. No. 6,583,124, the contents of which are incorporated herein by reference. If desired, liquid ophthalmic formulations have properties similar to that of lacrimal fluids, aqueous humor or vitreous humor or are compatible with such fluids. A preferred route of administration is local administration (e.g., topical administration, such as eye drops, or administration via an implant).
[0195] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
[0196] Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0197] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0198] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In
addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
[0199] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0200] Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
[0201] For use in the methods of this invention, active compounds can be given per se or as a pharmaceutical composition containing, for example, about 0.1 to about 99.5% (more preferably, about 0.5 to about 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[0202] Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow-release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.
[0203] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0204] The selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt
or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[0205] By “therapeutically effective amount” is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).
[0206] In general, a suitable daily dose of a pharmaceutically active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
[0207] If desired, the effective daily dose of the pharmaceutically active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments of the present invention, the pharmaceutically active compound may be administered two or three times daily. In preferred embodiments, the pharmaceutically active compound will be administered once daily.
[0208] The patient receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
[0209] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0210] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0211] The compounds of the present invention may be administered in combination with one or more other drugs (1) to complement and/or enhance therapeutic efficacy of the therapeutic drug effect of the compound of the present invention, (2) to modulate pharmacodynamics, improve absorption improvement, or reduce dosage reduction of the therapeutic compound of the present invention, and/or (3) to reduce or ameliorate the side effects of the therapeutic compound of the present invention. For example, the different therapeutic compounds can be administered either in the same formulation or in a separate formulation, either concomitantly or sequentially. In some embodiments, the different therapeutic compounds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds. The respective compounds may be administered by the same or different route and the same or different method.
[0212] A concomitant medicine comprising the compounds of the present invention and other drug may be administered as a combination preparation in which both components are contained in a single formulation or administered as separate formulations. The administration by separate formulations includes simultaneous administration and or administration of the formulations separated by some time intervals. In the case of the administration with some time intervals, the compound of the present invention can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present invention, so long as the two compounds are simultaneously active in the patient at least some of the time during the combination therapy. The administration method of the respective drugs may be administered by the same or different route and the same or different method.
[0213] The dosage of the other drug can be properly selected, based on a dosage that has been clinically used, or may be a reduced dosage that is effective when administered in combination with a compound of the present invention. The compounding ratio of the compound of the present invention and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof. For example, the other drug may be used in an amount of about 0.01 to about 100 parts by mass, based on 1 part by mass of the compound of the present invention. The other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion. The other drug that complements and/or enhances the therapeutic efficacy of the compound of the present invention includes not only those that have already been discovered, but those that will be discovered in future, based on the above mechanism.
[0214] In some embodiments, a compound of the invention may be administered with nonchemical methods of cancer treatment. In some embodiments, a compound of the invention may be administered with radiation therapy. In some embodiments, a compound of the invention may be administered with surgery, with thermoablation, with focused ultrasound therapy, with cryotherapy, or with any combination of these.
Methods of treatment
[0215] Disclosed herein are methods for treating cancer that comprise administering a disclosed compound with an oral SERD. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is metastatic breast cancer. In some embodiments, the cancer is ER -positive, HR -positive or HER2-negative, advanced or metastatic breast cancer. In some embodiments, the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof. In some embodiments, the oral SERD is In some embodiments, the oral SERD is ZN-c5, D- 0502, or SHR9549, or a pharmaceutically acceptable salt thereof.
[0216] Tn some embodiments, the present invention provides methods for treating a breast cancer selected from the group consisting of hormone dependent breast cancer and hormone independent breast cancer. In some embodiments, the present invention provides methods wherein the breast cancer is metastatic. In some embodiments, the breast cancer is ER positive. In some embodiments, the breast cancer is HR positive.
[0217] Head and neck cancer is a term used to define cancer that develops in the mouth, throat, larynx, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these cancers are squamous cell carcinomas, or cancers that begin in the lining of the mouth, nose and throat. Tobacco use, heavy alcohol use, and infection with human papillomavirus (HPV) increase the risk of head and neck cancers. Eighty- five percent of head and neck cancers are linked to tobacco use, and 75 percent are associated with a combination of tobacco and alcohol use.
[0218] Most (about 90% to 95%) cancers of the stomach are adenocarcinomas. A stomach cancer or gastric cancer almost always is an adenocarcinoma. These cancers develop from the cells that form the innermost lining of the stomach (the mucosa).
[0219] Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma.
[0220] In some embodiments, the present invention provides methods for treating cancer selected from head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, prostate cancer, soft-tissue sarcoma, adenocarcinoma, and lung cancer (e.g., non- small-cell lung cancer).
Solid Malignant Tumors
[0221] Sarcomas, carcinomas, melanomas, and glioblastomas are the main types of solid malignant tumors. Sarcomas are tumors in a blood vessel, bone, fat tissue, ligament, lymph vessel, muscle or tendon. Carcinomas are tumors that form in epithelial cells. Epithelial cells are found in the skin, glands and the linings of organs. Melanomas are tumors that develop in the pigment-containing cells known as melanocytes. Glioblastoma is an aggressive cancer that begins in the brain. They can either start from normal brain cells or develop from an existing low-grade astrocytoma. A solid tumor grows in an anatomical site outside the bloodstream (in contrast, for example, to cancers of hematopoietic origin such as leukemias) and requires the formation of small blood vessels and capillaries to supply nutrients, etc. to the growing tumor mass.
[0222] Non-limiting examples of solid malignant tumors include biliary cancer (e.g. , cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast),
brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma, glioblastomas; medulloblastoma), cervical cancer (e.g., cervical adenocarcinoma), colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma (OSCC)), kidney cancer (e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung), neuroblastoma, neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN)), prostate cancer (e.g., prostate adenocarcinoma), skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma, melanoma, basal cell carcinoma (BCC)) and soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myosarcoma, osteosarcoma).
Additional Malignancies
[0223] In addition to the cancers discussed above, the disclosed methods are useful in the treatment of a wide variety of cancers.
[0224] In some embodiments, the cancer is Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, Anal Cancer, Appendix Cancer, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Tumor, Astrocytoma, Brain and Spinal Cord Tumor, Brain Stem Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System Cancer, Cervical Cancer, Childhood Cancers, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma, Ductal Carcinoma In Situ (DCIS), Embryonal Tumors, Endometrial Cancer, Ependymoblastoma, Ependymoma, Esophageal Cancer, Esthesioneuroblastoma, Ewing Sarcoma, Extracranial Germ Cell Tumor,
Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, fibrosarcoma, Fibrous Histiocytoma of Bone, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), Germ Cell Tumor, Ovarian Germ Cell Tumor, Gestational Trophoblastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer, Hepatocellular Cancer, Histiocytosis, Langerhans Cell Cancer, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors, Kaposi Sarcoma, Kidney Cancer, Langerhans Cell Histiocytosis, Laryngeal Cancer, Leukemia, Lip and Oral Cavity Cancer, Liver Cancer, Lobular Carcinoma In Situ (LCIS), Lung Cancer, Lymphoma, AIDS-Related Lymphoma, Macroglobulinemia, Male Breast Cancer, Medulloblastoma, Medulloepithelioma, Melanoma, Merkel Cell Carcinoma, Malignant Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Myeloma, Multiple Myeloma, Chronic Myeloproliferative Disorder, Nasal Cavity Cancer, Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Oral Cavity Cancer, Lip Cancer, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumors of Intermediate Differentiation, Pineoblastoma, Pituitary Tumor, Plasma Cell Neoplasm, Pleuropulmonary Blastoma, Breast Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Clear cell renal cell carcinoma, Renal Pelvis Cancer, Ureter Cancer, Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoma, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer with Occult Primary, Squamous Cell Carcinoma of the Head and Neck (HNSCC), Stomach Cancer, Supratentorial Primitive Neuroectodermal Tumors, T-Cell Lymphoma, Testicular Cancer, Throat Cancer, Thymoma, Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Triple Negative Breast Cancer (TNBC), Gestational Trophoblastic Tumor, Unknown Primary, Unusual Cancer of Childhood, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Waldenstrom Macroglobulinemia, or Wilms Tumor.
[0225] In some embodiments, the cancer is carcinomas of the breast, liver, lung, colon, kidney, bladder, small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate, skin, squamous cell carcinoma, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, B- cell lymphoma, T- cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma, Burkett's lymphoma, hematopoietic tumors of myeloid lineage, acute and chronic myelogenous leukemias, myelodysplastic syndrome, promyelocytic leukemia, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma, tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannomas, seminoma, melanoma, osteosarcoma, teratocarcinoma, keratoacanthoma, xeroderma pigmentosum, thyroid follicular cancer and Kaposi's sarcoma.
[0226] In further embodiments of the invention, the cancer is selected from bladder cancer, breast cancer, esophageal cancer, gastric cancer, head & neck cancer, Kaposi’s sarcoma, lung cancer (including non-small cell lung cancer and small cell lung cancer), melanoma, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, testicular germ cell cancer, thymoma and thymic carcinoma.
[0227] In some embodiments, administering an oral SERD in combination with a compound of formula (I) provides improved efficacy relative to separately administering the compound of formula (I) or the oral SERD.
[0228] In some embodiments, administering an oral SERD in combination with a compound of formula (1) provides a synergistic effect.
[0229] Disclosed herein are methods for treating breast cancer that comprise administering a compound of formula (I) with an oral SERD. Also disclosed herein are methods for treating metastatic breast cancer.
[0230] In some embodiments, administering the oral SERD in combination with a compound of formula (I) provides improved efficacy for treating breast cancer relative to separately administering the compound of formula (I), or the oral SERD. In some embodiments, administering the oral SERD in combination with a compound of formula (I) provides a synergistic effect in treating breast cancer.
[0231] In some embodiments, the compound of formula (I) and the oral SERD are administered simultaneously or sequentially. In other embodiments, the oral SERD is administered within about 5 minutes to within about 168 hours prior to or after administration of the compound of formula (I).
[0232] Compounds suitable for the compositions and methods disclosed herein are disclosed in WO2016/193939 Al, published December 8, 2016, entitled “Substituted heterocyclyl derivatives as CDK inhibitors,” which is incorporated by reference in its entirety, and in particular for the compounds disclosed therein as CDK7 inhibitors.
EXAMPLES
Step 1 : Synthesis of 2-(3-bromophenyl)-3-methylbutanoic acid
[0233] 2M LDA (698 mL, 1.38 mol) was added to a solution of 2-(3 -bromophenyl) acetic acid (reagent 1, 150 g, 0.69 mol) in THF (700 mL) at -78 °C over a period of 30 min. The reaction mass was stirred for 2 h at -78 °C followed by the dropwise addition of isopropyl bromide (255g, 2.07mol) over a period of 30 min at -78 °C. The reaction mass was stirred at room temperature overnight. The reaction mass was quenched with IN HC1 (pH 2) and the product was extracted with ethyl acetate (500mL x 3). The combined organic layer was washed with water followed by brine, dried and concentrated under reduced pressure to afford the title crude compound which was purified by silica column chromatography with 0-
10% ethyl acetate-hexane to afford the title compound 2 (150g, 83% yield). LCMS: m/z = 254.80 (M-2H)-.
Step 2: Synthesis of tert-butyl 3-(2-(3-bromophenyl)-3-methylbutanamido)-5- cyclopropyl-lH-pyrazole-l-carboxylate
[0234] 2-(3-Bromophenyl)-3-methylbutanoic acid (intermediate 2, 70 g, 0.0.27mol) was dissolved in dry DCM (500 mL) and oxalyl chloride (68 mL, 0.78mol) was added dropwise at 0 °C followed by addition of a catalytic amount of DMF (0.8mL) and reaction mass was maintained at the same temperature for 30 min. The reaction mass was allowed to reach room temperature and stirred for 4 h, solvent was removed via distillation, and excess oxalyl chloride was removed under vacuum. The residue was re-dissolved in DCM (250 mL) and added slowly to a cooled solution of tert-butyl 3-amino-5-cyclopropyl-lH-pyrazole-l- carboxylate (intermediate 3, 49g, 0.218mol) and TEA (55 mL, 0.546 mol) in THF (250 mL) at 0 °C for 30 min. The reaction mixture was stirred at room temperature for 12 h, then the reaction mass was concentrated under reduced pressure. The resulting residue was dissolved in DCM, and washed with a saturated NaHCCh solution and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the crude was purified by silica gel column chromatography with 15% ethyl acetate-hexane to afford the title compound 4 (90 g, 71%) LCMS: m/z = 363.80 (M-Boc+2).
Step 3: Synthesis of tert-butyl 5-cyclopropyl-3-(3-methyl-2-(3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)butanamido)-lH-pyrazole-l-carboxylate
[0235] To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)-3-methylbutanamido)-5- cyclopropyl-lH-pyrazole-1 -carboxylate (intermediate-4, 90 g, 0.193 mol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (62g, 0.25 Imol) in 1,4-dioxane (500 mL) was added potassium acetate (37.80 g, 0.386 mol). The reaction mass was allowed to stir for 10 min with degassing at RT, and PdC12(dppf) DCM complex (12.5 g, 0.015 mol) was added. The reaction mass was heated for 3-4 h at 100 °C. The reaction mixture was cooled to RT and filtered on celite bed, and the filtrate was concentrated to afford a dark brown liquid. The crude material was purified by silica column chromatography by eluting with 20 % ethyl acetate in hexane to afford the title compound 5 (90 g, 86%). LCMS: m/z = 410 (M-Boc+1)+.
Step 4: Synthesis of (E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide
[0236] A degassed solution of tert-butyl 5-cyclopropyl-3-(3-methyl-2-(3-(4, 4,5,5- tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)phenyl)butanamido)- 1 H-pyrazole- 1 -carboxylate 5 (10 g, 0.019 mol) and (E)-N-(5-bromopyridin-2-yl)-4-morpholinobut-2-enamide 6 (7.7 g, 0.023 mol) in 1,4-dioxane (lOOmL) and water (40mL) was prepared, and CS2CO3 (14.5 g, 0.045 mol) was added. The reaction mass was allowed to stir for 10 min with degassing and Pd(PPh3)4 (1-1 g, 0.00095 mol) was added, followed by heating the reaction mass for 4 h at 100 °C in a sealed tube. The reaction mass was cooled and diluted with brine solution. The aqueous layer was separated and re-extracted with ethyl acetate. The combined organic layer was evaporated to dryness and the crude material was purified by silica column chromatography with 10%-l 5% methanol in DCM to afford the desired pure compound 44 (4.5g, 44%). LCMS: m/z = 529.15 (M+H)+; HPLC: 95.17%, rt: 6.34 min.
Step 5: Chiral Separation
[0237] Racemic (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 - oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide was separated by chiral preparative HPLC (Method: Column: Chiral Pak IA (20mm x 250 mm, 5 micron), Elution: isocratic (50:50), A=ACN, B= MeOH, Flow: 20mL/min ) to afford the pure 44A, i.e., (S)- (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide and 44B, i.e., (R)-(E)-N-(5-(3-(l-((5- cyclopropyl- 1 H-pyrazol-3-yl)amino)-3-methyl- 1 -oxobutan-2-yl)phenyl)pyridin-2-yl)-4- morpholinobut-2-enamide.
(5)-Isomer (Compound 44A):
[0238] 1 I INMR (DMSO-d6, 400MHz): 5 12.02 (s, 1H), 10.78 (s, 1H), 10.44 (s, 1H), 8.61 (s, 1H), 8.28 (d, 1H), 8.07-8.05 (m, 1H), 7.68 (s, 1H), 7.57 (d, 1H), 7.41-7.37 (m, 2H), 6.81- 6.78 (m, 1H), 6.49 (d, 1H), 6.13 (s, 1H), 3.61-3.58 (m, 4H), 3.36-3.34 (m, 1H), 3.12 (d, 2H), 2.41-2.32 (m, 5H), 1.82-1.76 (m, 1H), 0.97 (d, 3H), 0.88-0.85 (m, 2H), 0.67 (d, 3H), 0.62- 0.59 (m, 2H); LCMS: m/z = 529.15 (M+H)+; HPLC: 96.72%, rt: 6.39 min; Chiral HPLC: 97.68%, rt: 14.47.
(R)-Isomer (Compound 44B):
[0239] 'HNMR (DMSO-d6, 400MHz): 5 12.02 (s, 1H), 10.78 (s, 1H), 10.44 (s, 1H), 8.61 (s, 1H), 8.28 (d, 1H), 8.07-8.04 (m, 1H), 7.68 (s, 1H), 7.57 (d, 1H), 7.41-7.37 (m, 2H), 6.81- 6.78 (m, 1H), 6.50 (d, 1H), 6.14 (s, 1H), 3.61-3.58 (m, 4H), 3.36-3.34 (m, 1H), 3.12 (d, 2H),
2.40-2.39 (m, 5H), 1.82-1.76 (m, 1H), 0.97 (d, 3H), 0.88-0.85 (m, 2H), 0.67 (d, 3H), 0.62- 0.60 (m, 2H); LCMS: m/z = 529.15 (M+H)+; HPLC: 96.24%, it: 6.39 min; Chiral HPLC: 97.92%, rt: 8.80.
Example 2: Combination Studies of Compound 44A (CPD-44A) and oral SERDs [0240] This example describes the evaluation of the effect of therapeutic test agents in human breast cancer cell lines (MCF7, T47D, and BT474) by Cell Titer Gio Cell Viability Analysis.
[0241] This ex- vivo cell killing assay was conducted in a 384-well plate format (60 wells for test agent, plus 3 wells for vehicle control, and 3 wells for positive control), employing a 4-day incubation, and measuring ICso values with respect to Cell Titer Gio viability endpoints. Test articles in powder form were formulated in 100% DMSO. The Cell Titer Gio assay (Promega Cat# G7571) was conducted according to manufacturer instructions.
[0242] Cell lines received test agents as outlined below. For every cell line being studied, single agents and combinations were prepared in 384-well plates in technical duplicates, along with in-plate positive control and negative control.
Study Design for MCE7
[0243] Each cell group was a 12x8 combination matrix with duplicates per dose-point.
Highest stock concentrations used for this study design were 60 mM for CPD-44A and 2 mM for Amcenestrant, Giredestrant, Camizestrant, and Elacestrant.
Study Design for T47D and BT474
[0244] Each cell group was a 12x8 combination matrix with duplicates per dose-point.
Highest stocks used for this study design were 60 mM for CPD-44A and 2mM for Amcenestrant, Giredestrant, Camizestrant, Elacestrant.
[0245] Human cancer cells for every tumor type were seeded in 40 pL of appropriate media in a 384-well plate on Day 0. Therapeutic agents to be tested were added to wells on Day 1 according to the experimental design using a Tecan D300e digital dispenser. 10% DMSO was used as a positive control; media + vehicle (0.2%DMSO) was used as negative control. DMSO was adjusted in all wells corresponding to the highest vehicle control across plates and study designs. Plates were incubated at 37°C with 5% CO2. Media was not changed during the 4-day incubation period with test agents. The highest concentration of DMSO across all plates, cell lines and study designs was 0.2%. On day 5, cell viability was tested using the Cell Titer Gio assay.
[0246] Plates were removed from incubator and equilibrated to room temperature for up to 30 minutes. 20 pL of Cell Titer Gio reagent were added to wells and incubated at room temperature for 10 minutes to stabilize luminescent signal. Luminescence were recorded using a Tecan plate reader.
RESULTS
[0247] Figs. 1 -4 show the matrices for the assay results for the test agents at the tested concentrations in the MCF7 cell line. The assay results in Figs. 1-12 are reported as a viability ratio. Lower ratios indicate lower cell viability at the tested concentrations as compared to negative control.
[0248] Fig. 1 shows the matrix for CPD-44A + amcenestrant in the MCF7 cell line.
[0249] Fig. 2 shows the matrix for CPD-44A + giredestrant in the MCF7 cell line.
[0250] Fig. 3 shows the matrix for CPD-44A + camizestrant in the MCF7 cell line.
[0251] Fig. 4 shows the matrix for CPD-44A + elacestrant in the MCF7 cell line.
[0252] Figs. 5-8 show the matrices for the assay results for the test agents at the tested concentrations in the BT474 cell line.
[0253] Fig. 5 shows the matrix for CPD-44A + amcenestrant in the BT474 cell line.
[0254] Fig. 6 shows the matrix for CPD-44A + giredestrant in the BT474 cell line.
[0255] Fig. 7 shows the matrix for CPD-44A + camizestrant in the BT474 cell line.
[0256] Fig. 8 shows the matrix for CPD-44A + elacestrant in the BT474 cell line.
[0257] Figs. 9-12 show the matrices for the assay results for the test agents at the tested concentrations in the T47D cell line.
[0258] Fig. 9 shows the matrix for CPD-44A + amcenestrant in the T47D cell line.
[0259] Fig. 10 shows the matrix for CPD-44A + giredestrant in the T47D cell line.
[0260] Fig. 11 shows the matrix for CPD-44A + camizestrant in the T47D cell line.
[0261] Fig. 12 shows the matrix for CPD-44A + elacestrant in the T47D cell line.
[0262] Synergy scores for different dose combinations of CPD-44A with either amcenestrant, giredestrant, camizestrant, and elacestrant were calculated by the Loewe method using the Synergy Findcr+ web-based FAIR tool (sec, Zheng, ct al. Genomics, Proteomics & Bioinformatics 2022, 20, 587-596; Loewe. Ergebnisse der Physiologie 1928, 27, 47-187.) See, Figures 13-16. Unexpectedly low synergy scores were obtained for higher concentrations of the tested SERDs, indicating that it may be necessary to limit the amount of SERD compound administered to a particular subject in order to elicit a maximum therapeutic effect for the combination of SERD and CDK7 inhibitor.
[0263] Mouse Xenograft Model. Female, 7-8 week-old, NOD/SCID mice were purchased from GemPharmatech Co., and acclimated in the laboratory 1 week before experimentation. The animals were housed in microisolator cages, five per cage, in a 12-h light/dark cycle. The animals received filtered sterilized water and sterile rodent food ad libitum. The animals were observed daily, and clinical signs were noted. Each mouse was inoculated orthotopically at the right mammary fat pad region with MCF7 tumor cells (2 x 107) in 0.2 ml of PBS mixed with Matrigel (1:1) for tumor development. To support the growth of the estrogen-dependent MCF-7 tumor, a 0.36-mg 17P-estradiol 60-day release pellet (Innovative Research of America, Sarasota, FL) was implanted s.c. on the flank on the same side as the tumor implant one day prior to tumor implantation. The randomization started when the mean tumor size reached approximately 162 mm3. All animals were randomly allocated to 9 study groups, 10 mice in each group. Randomization was performed based on “Matched distribution” method (StudyDirector™ software, version 3.1.399.19).
[0264] Animals were treated with CPD-44A orally once daily for a total of 28 days. CPD- 44A is formulated in 0.5% Tween 80 + 0.5% methyl cellulose. Fulvestrant injection solution, purchased from AstraZeneca, was administered s.c. once weekly for the duration of study. Elacestrant, purchased from MedChemExpress, was formulated in 5%
DMSO/40%PEG400/5% Tween/50% saline, and administered orally once daily for the duration of study. Compounds were administered by exact body weight, with the administered volume being 1 Opl/ g body weight.
[0265] Tumors were measured and the animals weighed twice weekly. Tumor volume was determined by caliper measurements (mm) and using the formula for an ellipsoid sphere: L x W2 /2 mm3 . As shown in Figure 17, the combination of CPD-44A and elacestrant was found to be more effective in reducing tumor growth than either agent alone.
EXEMPLARY EMBODIMENTS
[0266] Exemplary embodiments according to the present disclosure include, but are not limited to, those recited in the appended claims and the following embodiments.
1. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with a therapeutically effective amount of an oral selective estrogen receptor degrader (SERD); wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl; ring B is aryl, cycloalkyl, heteroaryl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
R2 is hydrogen, alkyl or cycloalkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
R5 is:
R5' is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or -(CH2)i-3-NRaRb,
R5" is H or alkyl, and
Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl, or alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S, wherein the optional substituent is independently one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl;
Re at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
Li is *-CRcRd-C(O)-, *-NReC(O)- or absent, wherein * is the point of attachment with ring A;
Rc and Rd independently are hydrogen, alkyl or haloalkyl, or alternatively, Rc and Ra together with the carbon to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is -C(O)NH- -C(O)O- or absent; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
2. The method of embodiment 1 , wherein the compound is represented by formula (IA):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein:
R4 at each occurrence is halo, alkyl, hydroxy or alkoxy; and
Ra and Rb together with the nitrogen atom to which they are attached form the optionally substituted ring, wherein the optional substituent is independently one or more halo, alkyl, hydroxy, haloalkyl or alkoxy.
3. The method of embodiment 1, wherein the compound is represented by formula (IB):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
4. The method of embodiment 1 , wherein the compound is represented by formula (IC):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
5. The method of embodiment 1, wherein the compound is represented by formula (ID):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
6. The method of embodiment 1 , wherein the compound is represented by formula (IE):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Li is *-CRcRd-C(O)- or *-NReC(O)-; and wherein * is the point of attachment with phenyl ring.
7. The method of embodiment 1, wherein the compound is represented by formula (IF):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein Li is *-CRcRd-C(O)- or *-NReC(O)-; and wherein * is the point of attachment with phenyl ring. 8. The method of embodiment 1, wherein the compound is represented by formula (IG):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
9. The method of any one of embodiments 1 , 2, 4, and 8 wherein ring A is aryl or heteroaryl.
10. The method of any one of embodiments 1, 2, 4, 8, and 9 wherein ring A is aryl.
11. The method of any one of embodiments 1-5, 9, and 10, wherein ring B is cycloalkyl, aryl, heterocycloalkyl or heteroaryl, each of which is monocyclic or bicyclic.
12. The method of any of the embodiments 1-5 and 8-11, wherein R2 is cycloalkyl.
14. The method of any one of embodiments 1-13, wherein R5' is -(CH2)I-
3-NRaRh.
15. The method of embodiment 13 or embodiment 14, wherein Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N.
16. The method of any one of embodiments 1-15, wherein Li is *-CRcRd- C(O)-; wherein * is the point of attachment with ring A.
17. The method of any one of embodiments 1-3 and 9-16, wherein L2 is absent.
18. The method of embodiment 1, wherein the compound of formula (I) is selected from:
or a pharmaceutically acceptable salt or a stereoisomer thereof.
19. The method of embodiment 1, wherein the compound of formula (I) is selected from:
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3 -fluoropyrrolidin- 1 -yl)but-2-enamide;
N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-l-oxopropan-2- yl)phenyl)pyridin-2-yl)acrylamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; (E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phcnyl)pyridin-2-yl)-4-(pyrrolidin- 1 -yl)but-2-cnamidc;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(piperidin- 1 -yl)but-2-enamide;
(E)-N-(3'-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2- yl)-3-fluoro-[l,r-biplieiiyl]-4-yl)-4-(diniethylamino)but-2-enamide; and
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(3 -fluoropiperidin- 1 -yl)but-2-enamide.
20. The method of embodiment 1, wherein the compound of formula (I) is selected from:
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin- 1 -yl)but-2-enamide; and
(E)-N -(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
21. The method of embodiment 1, wherein the compound of formula (I) is (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
22. The method of embodiment 1, wherein the compound of formula (I) is (1S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
23. The method of embodiment 1, wherein the compound of formula (I) is (R)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
24. The method of any one of embodiments 1-23, wherein administering an oral SERD in combination with a compound of formula (I) provides improved efficacy relative to separately administering the compound of formula (I) or the oral SERD.
25. The method of any one of embodiments 1 -24, wherein administering the oral SERD in combination with a compound of formula (I) provides a synergistic effect.
26. The method of any one of embodiments 1-25, wherein the compound of formula (I) and the oral SERD are administered simultaneously or sequentially.
27. The method of any one of embodiments 1-26, wherein the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
28. The method of any one of embodiments 1-27, wherein the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ- 102, or a pharmaceutically acceptable salt thereof.
29. The method of embodiment 28, wherein the oral SERD is elacestrant or a pharmaceutically acceptable salt thereof.
30. The method of embodiment 28, wherein the oral SERD is rintodestrant or a pharmaceutically acceptable salt thereof.
31. The method of embodiment 28, wherein the oral SERD is giredestrant or a pharmaceutically acceptable salt thereof.
32. The method of embodiment 28, wherein the oral SERD is amcenestrant or a pharmaceutically acceptable salt thereof.
33. The method of embodiment 28, wherein the oral SERD is camizestrant or a pharmaceutically acceptable salt thereof.
34. The method of embodiment 28, wherein the oral SERD is imlunestrant or a pharmaceutically acceptable salt thereof.
35. The method of embodiment 28, wherein the oral SERD is LSZ-102 or a pharmaceutically acceptable salt thereof.
36. The method of any one of embodiments 1-35, wherein the cancer is breast cancer.
37. The method of embodiment 36, wherein the breast cancer is metastatic breast cancer.
38. The method of embodiment 36, wherein the breast cancer is ERpositive, HR-positive or HER2 -negative, advanced or metastatic breast cancer.
39. The method of embodiment 38, wherein the breast cancer is ERpositive breast cancer.
40. The method of embodiment 38, wherein the breast cancer is HRpositive breast cancer.
41. The method of any one of embodiments 1-35, wherein the cancer is prostate cancer.
42. The method of any one of embodiments 1-35, wherein the cancer is ovarian cancer.
43. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of (5)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of an oral SERD.
44. The method of embodiment 43, wherein the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
45. The method of embodiment 43 or 44, wherein the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
46. The method of embodiment 45, wherein the cancer is breast cancer.
47. The method of any one of embodiments 1-47, wherein the compound of formula (I) and the oral SERD are each administered orally.
48. The method of embodiment 47, wherein the compound of formula (I) and the oral SERD are administered in a single composition.
49. The method of embodiment 47, wherein the compound of formula (I) and the oral SERD are administered in separate compositions.
50. The method of any one of embodiments 1-49, wherein the compound of formula (I) is (5)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide fumarate.
51. The method of embodiment 50, wherein the (S)-(E)-N-(5-(3-(l-((5- cyclopropyl- 1 H-pyrazol-3-yl)amino)-3-methyl- 1 -oxobutan-2-yl)phenyl)pyri din-2 -yl)-4- morpholinobut-2-enamide fumarate is crystalline Form 1.
52. The method of any one of embodiments 1-51, wherein the oral SERD is elacestrant.
53. The method of embodiment 52, wherein the elacestrant is administered at a total daily dose of from about 25 to about 250 mg.
54. The method of any one of embodiments 1-51, wherein the oral SERD is giredestrant.
55. The method of embodiment 54, wherein the giredestrant is administered at a total daily dose of from about 1 mg to about 25 mg.
56. The method of any one of embodiments 1-51, wherein the oral SERD is amcenestrant.
57. The method of embodiment 56, wherein the amcenestrant is administered at a total daily dose of from about 10 mg to about 200 mg.
58. The method of any one of embodiments 1-51, wherein the oral SERD is camizestrant.
59. The method of embodiment 58, wherein the camizestrant is administered at a total daily dose of from about 2 mg to about 50 mg.
Other Embodiments
[0267] The foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining
within the spirit and scope of the invention. It will be obvious to one of skill in the art that changes and modifications can be practiced within the scope of the appended claims.
Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.
Claims
1. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (T):
or a pharmaceutically acceptable salt or a stereoisomer thereof, in combination with a therapeutically effective amount of an oral selective estrogen receptor degrader (SERD); wherein, ring A is aryl, cycloalkyl, heteroaryl or heterocyclyl; ring B is heteroaryl, aryl, cycloalkyl, heterocyclyl or absent;
Ri is hydrogen or alkyl;
Ri is cycloalkyl, hydrogen or alkyl;
R3 is hydrogen, alkyl or heteroaryl; alternatively, R2 together with Ri or R3 along with the ring atoms to which they are attached forms a 5- to 7-membered ring;
R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
R5" is H or alkyl, and
Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is independently one or more halo, alkyl, acyl,
hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, -COOH or -COO-alkyl, or alternatively,
Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively;
R6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
Li is *-CRcRd-C(O)-, *-NReC(O)- or absent, wherein * is the point of attachment with ring A;
Rc and Rd independently are hydrogen, alkyl or haloalkyl, or alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
Re is hydrogen or alkyl;
L2 is absent -C(O)NH- or-C(O)O-; m is 0, 1 or 2; p is 0 or 1; and q is 0 to 3.
2. The method of claim 1, wherein the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein the compound is represented by formula (IA):
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein:
R4 at each occurrence is halo, alkyl, hydroxy or alkoxy; and
5. The method of claim 1, wherein ring A is aryl or heteroaryl.
6. The method of claim 1 , wherein ring B is cycloalkyl, aryl, heterocycloalkyl or heteroaryl, each of which is monocyclic or bicyclic.
7. The method of claim 1, wherein R2 is cycloalkyl.
9. The method of claim 8, wherein R5' is -(CH2)i-3-NRaRh.
10. The method of claim 9, wherein Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N.
11. The method of claim 1, wherein Li is *-CRcR<i-C(O)-.
12. The method of claim 1 , wherein T2 is absent.
13. The method of claim 1, wherein the compound of formula (I) is selected from:
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-l-yl)but-2-enamide;
N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-l-oxopropan-2- yl)phenyl)pyridin-2-yl)acrylamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-l -yl)but-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(piperidin- 1 -yl)but-2-enamide;
(E)-N-(3'-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2- yl)-3-fluoro-[l,T-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; and
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(3 -fluoropiperidin- 1 -yl)but-2-enamide.
14. The method of claim 1, wherein the compound of formula (I) is selected from:
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3-methyl- 1 -oxobutan- 2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide;
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin- 1 -yl)but-2-enamide; and
(E)-N-(5 -(3-( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)- 1 -oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
15. The method of claim 1, wherein the compound of formula (I) is (E)-N- (5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin- 2-yl)-4-morpholinobut-2-enamide.
16. The method of claim 1, wherein the compound of formula (I) is (S)- (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
17. The method of claim 1, wherein the compound of formula (I) is (R)- (E)-N-(5 -(3 -( 1 -((5 -cyclopropyl- 1 H-pyrazol-3 -yl)amino)-3 -methyl- 1 -oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide.
18. The method of claim 1, wherein the compound of formula (I) and the oral SERD are administered simultaneously or sequentially.
19. The method of claim 1, wherein the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
20. The method of any one of claims 1-19, wherein the cancer is breast cancer.
21. The method of claim 20, wherein the breast cancer is metastatic breast cancer.
22. The method of claim 20, wherein the breast cancer is ER-positive, HRpositive or HER2 -negative, advanced or metastatic breast cancer.
23. The method of claim 22, wherein the breast cancer is ER-positive breast cancer.
24. The method of claim 22, wherein the breast cancer is HR-positive breast cancer.
25. The method of any one of claims 1-19, wherein the cancer is prostate cancer.
26. The method of any one of claims 1-19, wherein the cancer is ovarian cancer.
27. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH- pyrazol-3-yl)amino)-3-methyl-l-oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2- enamide or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of an oral SERD.
28. The method of claim 27, wherein the oral SERD is elacestrant, rintodestrant, giredestrant, amcenestrant, camizestrant, imlunestrant, or LSZ-102, or a pharmaceutically acceptable salt thereof.
29. The method of claim 27 or 28, wherein the cancer is breast cancer, prostate cancer, head and neck cancer, squamous cell carcinoma, stomach cancer, ovarian cancer, soft-tissue sarcoma, adenocarcinoma, or lung cancer.
30. The method of claim 29, wherein the cancer is breast cancer.
31. The method of any one of claims 1-31, wherein the compound of formula (I) and the oral SERD are each administered orally.
32. The method of claim 31 , wherein the compound of formula (I) and the oral SERD are administered in a single composition.
33. The method of claim 31, wherein the compound of formula (I) and the oral SERD are administered in separate compositions.
34. The method of any one of claims 1-33, wherein the compound of formula (I) is (S)-(E)-N-(5-(3-(l-((5-cyclopropyl-lH-pyrazol-3-yl)amino)-3-methyl-l- oxobutan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide fumarate.
35. The method of claim 34, wherein the (5)-(E)-N-(5-(3-(l-((5- cyclopropyl- 1 H-pyrazol-3-yl)amino)-3-methyl- 1 -oxobutan-2-yl)phenyl)pyri din-2 -yl)-4- morpholinobut-2-enamide fumarate is crystalline Form 1.
36. The method of any one of claims 1-35, wherein the oral SERD is elacestrant.
37. The method of claim 36, wherein the elacestrant is administered at a total daily dose of from about 25 to about 250 mg.
38. The method of any one of claims 1-35, wherein the oral SERD is giredestrant.
39. The method of claim 38, wherein the giredestrant is administered at a total daily dose of from about 1 mg to about 25 mg.
40. The method of any one of claims 1-35, wherein the oral SERD is amcenestrant.
41. The method of claim 40, wherein the amcenestrant is administered at a total daily dose of from about 10 mg to about 200 mg.
42. The method of any one of claims 1-35, wherein the oral SERD is camizestrant.
43. The method of claim 42, wherein the camizestrant is administered at a total daily dose of from about 2 mg to about 50 mg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263342470P | 2022-05-16 | 2022-05-16 | |
US63/342,470 | 2022-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023224961A1 true WO2023224961A1 (en) | 2023-11-23 |
Family
ID=86760483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/022340 WO2023224961A1 (en) | 2022-05-16 | 2023-05-16 | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023224961A1 (en) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6583124B2 (en) | 1997-07-29 | 2003-06-24 | Alcon Manufacturing, Ltd. | Ophthalmic compositions containing galactomannan polymers and borate |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050080056A1 (en) | 1999-09-16 | 2005-04-14 | Gerald Horn | Ophthalmic formulations including selective alpha 1 antagonists |
US7612114B2 (en) | 2002-12-26 | 2009-11-03 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulator |
WO2016193939A1 (en) | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
US10071066B2 (en) | 2014-03-28 | 2018-09-11 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
WO2018231859A1 (en) * | 2017-06-12 | 2018-12-20 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
US10385008B2 (en) | 2017-01-05 | 2019-08-20 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCL |
US10420734B2 (en) | 2014-03-28 | 2019-09-24 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
CN110590747A (en) * | 2018-06-12 | 2019-12-20 | 隆泰申医药科技(南京) 有限公司 | Compound, preparation method, pharmaceutical composition and application thereof |
WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
WO2022130304A1 (en) | 2020-12-18 | 2022-06-23 | Aurigene Discovery Technologies Ltd. | Cocrystal of a cdk inhibitor |
WO2022229835A1 (en) | 2021-04-27 | 2022-11-03 | Aurigene Discovery Technologies Limited | Process for preparing a cdk inhibitor |
WO2022249141A2 (en) * | 2021-05-28 | 2022-12-01 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent |
WO2023107861A1 (en) * | 2021-12-06 | 2023-06-15 | Exelixis, Inc. | Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer |
-
2023
- 2023-05-16 WO PCT/US2023/022340 patent/WO2023224961A1/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6583124B2 (en) | 1997-07-29 | 2003-06-24 | Alcon Manufacturing, Ltd. | Ophthalmic compositions containing galactomannan polymers and borate |
US20050080056A1 (en) | 1999-09-16 | 2005-04-14 | Gerald Horn | Ophthalmic formulations including selective alpha 1 antagonists |
US7612114B2 (en) | 2002-12-26 | 2009-11-03 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulator |
US8399520B2 (en) | 2002-12-26 | 2013-03-19 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulator |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US10071066B2 (en) | 2014-03-28 | 2018-09-11 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
US10420734B2 (en) | 2014-03-28 | 2019-09-24 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
WO2016193939A1 (en) | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
US10385008B2 (en) | 2017-01-05 | 2019-08-20 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCL |
US10745343B2 (en) | 2017-01-05 | 2020-08-18 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCl |
WO2018231859A1 (en) * | 2017-06-12 | 2018-12-20 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN110590747A (en) * | 2018-06-12 | 2019-12-20 | 隆泰申医药科技(南京) 有限公司 | Compound, preparation method, pharmaceutical composition and application thereof |
WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
WO2022130304A1 (en) | 2020-12-18 | 2022-06-23 | Aurigene Discovery Technologies Ltd. | Cocrystal of a cdk inhibitor |
WO2022229835A1 (en) | 2021-04-27 | 2022-11-03 | Aurigene Discovery Technologies Limited | Process for preparing a cdk inhibitor |
WO2022249141A2 (en) * | 2021-05-28 | 2022-12-01 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent |
WO2023107861A1 (en) * | 2021-12-06 | 2023-06-15 | Exelixis, Inc. | Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer |
Non-Patent Citations (12)
Title |
---|
BRETT ET AL., BREAST CANCER RES, vol. 23, 2021, pages 85 |
CARRICK THERAPEUTICS LTD.: "Carrick Therapeutics Announces Collaboration with Roche to", 1 January 2021 (2021-01-01), pages 1 - 3, XP093066478, Retrieved from the Internet <URL:https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2021%2F08%2F02%2F2272838%2F0%2Fen%2FCarrick-Therapeutics-Announces-Collaboration-with-Roche-to-Evaluate-Novel-Samuraciclib-Combination-to-Treat-HR-Breast-Cancer.html> [retrieved on 20230724] * |
COOMBES CHARLES ET AL: "Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) | Cancer Research | American Association for Cancer Research", 15 February 2022 (2022-02-15), pages 1 - 4, XP093066912, Retrieved from the Internet <URL:https%3A%2F%2Faacrjournals.org%2Fcancerres%2Farticle%2F82%2F4_Supplement%2FGS3-10%2F680183%2FAbstract-GS3-10-Study-of-samuraciclib-CT7001-a> [retrieved on 20230724] * |
FISHER ET AL., CELL, vol. 78, no. 4, 26 August 1994 (1994-08-26), pages 713 - 24 |
GANUZA ET AL., EMBO J, vol. 31, no. 11, 30 May 2012 (2012-05-30), pages 2498 - 510 |
ISSELBACHER ET AL.: "Harrison's Principles of Internal Medicine", vol. 13, 1996, pages: 1814 - 1882 |
JOHANNESSEN ET AL: "Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications | Molecular Cancer Therapeutics | American Association for Cancer Re", 1 December 2019 (2019-12-01), pages 1 - 5, XP093066915, Retrieved from the Internet <URL:https%3A%2F%2Faacrjournals.org%2Fmct%2Farticle%2F18%2F12_Supplement%2FC091%2F239833%2FAbstract-C091-Preclinical-evaluation-of-PK-PD-and> [retrieved on 20230724] * |
LAROCHELLE ET AL., MOL CELL, vol. 25, no. 6, 23 May 2007 (2007-05-23), pages 839 - 50 |
LOEWE, ERGEBNISSE DER PHYSIOLOGIE, vol. 27, 1928, pages 47 - 187 |
ONCOGENE, vol. 21, 2002, pages 4921 |
YU: "Abstract 5977: Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor | Cancer Research | American Association for Cancer Research", 1 April 2023 (2023-04-01), pages 1 - 4, XP093066930, Retrieved from the Internet <URL:https%3A%2F%2Faacrjournals.org%2Fcancerres%2Farticle%2F83%2F7_Supplement%2F5977%2F719373> [retrieved on 20230724] * |
ZHENG ET AL., GENOMICS, PROTEOMICS & BIOINFORMATICS, vol. 20, 2022, pages 587 - 596 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200345704A1 (en) | Compounds and compositions for treating hematological disorders | |
EP3600270B1 (en) | Compounds and compositions for treating hematological disorders | |
US11065239B2 (en) | Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor | |
TW201836606A (en) | Combination use of mor agonist and kor agonist in the preparation of a medicament for the remission and/or treatment of pain | |
JP2018517672A (en) | Isoxazolyl-substituted imidazopyridines | |
CN105120868A (en) | Combination therapy | |
WO2022249141A2 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
US20240016811A1 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent | |
WO2022159986A1 (en) | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer | |
CN115768423A (en) | Inhibitors of EGFR, KRAS, BRAF and other targets and uses thereof | |
US20200268728A1 (en) | Drug targeting cancer stem cell | |
WO2023107861A1 (en) | Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer | |
WO2023224961A1 (en) | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd | |
RU2624493C2 (en) | 2-carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for treating proliferative diseases | |
JPWO2018186366A1 (en) | Novel cyclin dependent kinase 8 and / or 19 inhibitors | |
JP7223998B2 (en) | Solid cancer therapeutic agent containing an Axl inhibitor as an active ingredient | |
AU2021255084A1 (en) | Breast cancer therapeutic agent | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
WO2014058785A1 (en) | Combination therapy | |
NZ757707B2 (en) | Compounds and compositions for treating hematological disorders | |
WO2011128434A2 (en) | Treatment of endocrine resistant breast cancer | |
WO2012026511A1 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23730295 Country of ref document: EP Kind code of ref document: A1 |